**Name of Journal: *World Journal of Meta-Analysis***

**Manuscript NO: 33763**

**Manuscript Type: Systematic Reviews**

**Medication non-adherence in bipolar disorder: Review of rates, demographic and clinical predictors**

Chakrabarti S. Medication non-adherence in bipolar disorder

**Subho Chakrabarti**

**Subho Chakrabarti,** Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India

**Author contributions:** Chakrabarti S solely contributed to this paper.

**Conflict-of-interest statement:** No conflicts of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Subho Chakrabarti, MD, FAMS, FRCPsych, Professor,** Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012, India. subho@pgimer.edu.in

**Telephone:** +91-172-2756808

**Fax:** +91-172-2744401

**Received:** February 28, 2017

**Peer-review started:** March 2, 2017

**First decision:** April 18, 2017

**Revised:** May 31, 2017

**Accepted:** June 12, 2017

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To conduct a systematic search for all studies examining rates and demographic and illness-related determinants of medication non-adherence in bipolar disorder (BD).

***METHODS***

A comprehensive literature search was undertaken of six English-language databases to identify published articles on medication non-adherence in BD from inception till December 2016. Any article, either a review or an original-research article was examined for its relevance to the subject. All such articles were manually searched to locate any further articles containing relevant information. Studies were included only if they had adequately described the patient sample, assessment methods and statistical procedures, presented their results systematically and their conclusions were congruent with the results.

***RESULTS***

The initial search yielded 249 articles on the subject; of these 198 articles were included. Of the 162 original-research studies, 132 had provided information on rates of medication non-adherence in BD. There was a wide variation in rates ranging from universal adherence (100%) to almost universal non-adherence (96%); this discrepancy was more due to methodological differences than true variations in rates. Notwithstanding the significant discrepancies in methodology, based on these 132 studies mean rates of 41.5%-43% and median rates of 40%-41% were obtained for medication non-adherence in BD. Rates of adherence with mood stabilizers were significantly lower than those for antipsychotics, or for medications of all classes. None of the demographic attributes were unequivocally linked to medication non-adherence in BD. Similarly, medication-related variables such as type of medications, doses, treatment regimens and side effects did not demonstrate consistent associations with non-adherence. Among clinical characteristics the presence of comorbid substance use disorder and absence of insight were the only two factors clearly linked to non-adherence in BD.

***CONCLUSION***

Medication non-adherence is prevalent in about a third to half of patients with BD. Demographic, illness and treatment related factors do not predict non-adherence with certainty.

**Key words:** Medications; Non-adherence; Bipolar disorder; Rates; Demographics; Illness characteristics; Treatment variables

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Based on existing reviews non-adherence is estimated to be present in 25%-42% of patients with bipolar disorder (BD). The present, more comprehensive review comprising of 198 studies found mean rates of 41.5%-43% and median rates of 40%-41% for medication non-adherence in BD. Neither demographic characteristics nor medication-related variables were unequivocally linked to medication non-adherence in BD, while comorbid substance use disorder and absence of insight were the only two clinical factors consistently associated with non-adherence in BD. The failure of clinical and demographic factors to predict non-adherence emphasizes the importance of other patient orientated factors in determining non-adherence in BD.

Chakrabarti S. Medication non-adherence in bipolar disorder: Review of rates, demographic and clinical predictors. *World J Meta-Anal* 2017; In press

**INTRODUCTION**

Bipolar disorder (BD) is prototypical of all chronic medical conditions with enduring symptoms, residual disability and the need for long-term care[1,2]. Like other such conditions, non-adherence with treatment is very common among patients with BD and associated with a range of adverse consequences such as poor clinical outcomes, functional impairment, impaired quality of life, increased health-service utilization and higher costs of care[2-4].

Several reviews on the subject have estimated non-adherence rates in BD to range from around 8% to 68% with mean rates varying from 25% to 40% across these reviews[5-8]. Despite this wide variation in rates the median rate of non-adherence, which is probably a more true measure of non-adherence, has been fairly stable at 40% to 42% in different reviews. However, it is somewhat surprising that despite there being over 100 studies on treatment non-adherence in BD, most of these reviews have not included more than a handful of studies. Moreover, the majority of reviews are somewhat dated and have not systematically and comprehensively searched the existing literature to identify all possible studies relating to non-adherence in BD. Those that have systematically reviewed the existing literature (*e.g*., Busby and Sajatovic[3]) appeared to have used very stringent selection criteria limiting the number of studies they have included.

The correlates of non-adherence in BD have been traditionally categorized into patient-related, illness-related, treatment-related and physician-related factors[9-12]. The majority of studies have, however, examined demographic correlates like age, gender, marital status, or clinical features such as age of onset, longitudinal course, symptom-severity, insight and comorbidity, or medication-related variables such as the class of medications, number and doses of medications and side effects associated with treatment[3,13,14]. However, results of these studies have been largely inconsistent, leading to considerable uncertainty regarding which of these factors truly influence non-adherence in BD[8,13]. Consequently, there is little consensus among reviews regarding the clinical, demographic and treatment-related determinants of medication non-adherence in BD. Moreover, similar to the reviews on the rates of non-adherence in BD, reviews examining correlates of non-adherence are based on a limited number of studies.

Given these drawbacks of existing reviews on rates and correlates of medication non-adherence in BD, the present review aimed to conduct a more comprehensive and systematic search for all possible studies of BD, which have investigated these aspects. The principal objective was to estimate rates of medication non-adherence in BD and examine its demographic, illness and medication related correlates based on a much wider selection and a larger number of studies than those that have been included as a part of earlier reviews.

**MATERIALS AND METHODS**

A comprehensive literature search was undertaken using the following six English-language databases: MEDLINE, PubMed, PsycINFO, EMBASE, Cochrane and Google to identify published articles on medication non-adherence in BD from inception till December 2016. Search terms included BD, bipolar depression or mania used in conjunction with other terms including adherence, compliance, concordance, non-adherence, non-compliance, determinants, predictors, treatment and medication. Any article, either a review or an original research article (based on clinical trials or observational studies) was examined for its relevance to the subject. All such articles were manually searched to locate any further articles, which were judged to be containing information pertaining to the topic. In an effort to identify and include as many studies as possible the initial criteria for selection were broad and inclusive. Any article that had provided information on rates and/or demographic, clinical or treatment correlates of medication non-adherence in BD was included. Articles dealing with other forms of adherence, *e.g.*, appointment adherence or attendance for psychosocial interventions were considered only if they had provided information on medication adherence. Both quantitative and qualitative studies were included. Final selection, however, also depended on the quality of studies, which was assessed partly based on criteria used in previous reviews[12,15]. Studies were included only if they had adequately described the source and nature of the patient sample, the methods of ascertaining relevant variables and the statistical procedures followed. Additionally, for any study to be incorporated its results should have been presented systematically and the conclusions should have been congruent with the results of the study.

***Statistical analysis***

Statistical analyses consisted mainly of estimation of mean and median rates. Student’s *t* test was used to compare the non-adherence rates among different classes of medications. This was approved by the biostatistics department of the institution.

**RESULTS**

The initial search yielded 249 articles on the subject; 43 of these were reviews and 206 were original research articles. Of these 51 articles (7 reviews and 44 original research articles) were excluded. Though these 51 articles did deal with some aspect of treatment adherence in BD the principal reason for excluding them was the lack of information either on rates of medication non-adherence or on demographic, illness or treatment related correlates of non-adherence in BD. Thus, the final list included 198 articles; 36 of these were reviews and 162 were original research articles.

***Rates of medication non-adherence in BD***

**Reviews:** Table 1 lists the reviews on rates of non-adherence in BD. The most commonly quoted reviews are the ones by Lingam and Scott[6] and Perlick *et al*[7], both of which have found rates ranging from about 20% to 68% with median rates of about 41% to 42% for non-adherence in BD. Other reviews included in the table also indicate that non-adherence rates vary from 8%-64% with mean rates of 25% to 40% and median rates of 40% to 41% for all classes of medications. Reviews on lithium estimate non-adherence rates to lie between 9% to 57%, while one review found the rates to vary from 23%-60% among patients on antipsychotics[16]. The wide variation in rates (from 8% to 68%) was most likely to be due to differences in methodology adopted by individual studies[4]. Moreover, the number of studies, from which these rates are derived was quite small in most reviews. Only Pompili *et al*[10] have included 104 articles on mood disorders from 1975 to 2009, but the number of studies from which the non-adherence rate for BD was derived was not clear. Despite these disparities and limitations it was evident that about a quarter to half of the patients with BD were fully or partially non-adherent[15,17]. This rate was similar to other chronic medical disorders including psychiatric and physical disorders[1,4,18]. There appeared to be no substantial differences between rates of non-adherence for mood stabilizers (principally lithium carbonate) and those for antipsychotics[4]. Similarly, no differences in rates between older or newer medications were noted. Indeed, studies conducted decades apart have revealed that rates of non-adherence have remained the same over the years despite the availability of many new types of medications[4,6,10,13,19].

**Studies:** Tables 2-4 list the 132 studies ofthis review providing an estimate of medication non-adherence in BD. Studies spanned exactly four decades with the first study conducted by Bech *et al*[30] among patients on lithium in 1976. The number of studies with patients on all classes of medications (*n =* 69) was the highest followed by studies of patients on mood stabilizers (*n =* 46). There were 15 studies of patients on antipsychotics and only two of patients on antidepressants. The majority of the studies were conducted in Western settings with barely 20 studies from non-Western countries. Not surprisingly, there was a wide variation in rates from universal adherence (100%) to almost universal non-adherence (96%). This was obviously more as a result of methodological differences across studies rather than a true variation in rates. Studies differed in the number of patients included, the duration during which adherence was assessed and the techniques used to assess adherence. The majority of studies had sample sizes ranging from 100 to 500 patients (*n =* 51; 39%); but about a third had included 50 to 100 patients (*n =* 37; 28%), while 20% of the studies (*n =* 26) had less than 50 patients. Most studies were conducted over the period of 1 mo to 1 year (*n =* 56; 42%), but cross-sectional studies were also very common (*n =* 37; 28%), whereas about a quarter of the studies (*n =* 33; 25%) had extended beyond 1 year, often up to several years in some studies of mood stabilizers. About a third of the studies had used multiple measures to estimate adherence (*n =* 38; 29%), even as studies based only on self-reports (*n =* 37; 28%), or only on clinical interviews (*n =* 34; 26%) were equally common. Fifteen studies (11%) were based on analysis of claims data.

Rates were computed using the highest rate of non-adherence where multiple rates were mentioned and rates at baseline for longitudinal studies. Despite significant discrepancies in methodology across studies, when rates were computed from all the 132 studies the mean rate of non-adherence turned out to be 41.5% (41.52 ± 19.56) and the median rate was 40%. Rates of non-adherence were between 25% to 50% in 65 studies (49%) and greater than 50% in 42 of the 132 studies (32%).

Most studies with very high rates of non-adherence (> 80%) were either part of randomized-controlled trials[31], or had been conducted among inpatients or mental hospital populations[32-34], or were studies with qualitative designs[35,36]. Patient numbers were generally small in these studies. Similarly, studies with very low rates of non-adherence (< 20%) were either from specialized lithium clinics[37,38], or were derived from randomized-controlled trials[39-42]. Others studies with very low rates had relied either exclusively on patient reports to estimate non-adherence[43-45], or had used qualitative designs with small patient samples[46]. In contrast, the average rate of non-adherence in the 18 studies with large and more representative samples (naturalistic studies with > 500 patients) was higher at 49% (48.81 ± 14.13). The mean rate of adherence in the studies which had lasted more than 1 year was lower at 36% (36.36 ± 12.90). However, even after excluding the 21 studies with very high or very low rates, the mean rate of non-adherence in BD increased only to 43% (42.81 ± 14.66) and the median rate to 41%.

The average rate of non-adherence derived from studies where patients received all classes of medication was 45% (44.62 ± 19.61) with a median of 41%; after excluding 11 studies with very high or very low rates the mean rate was still 45% (44.94 ± 14.95), while the median rate increased to 43.5%. The mean rate of non-adherence among patients on mood stabilizers was 34% (34.16 ± 18.35) and the median rate was 31.5%. After excluding 9 studies with very high or very low rates the mean increased to 38% (37.82 ± 13.24) and the median to 34%. Rates derived from studies of antipsychotic medications were the highest with a mean of 51% (50.87 ± 15.87) and a median of 48%. After excluding one study with a very high rate the mean dropped to 48% (48.43 ± 13.44) and the median to 47%. Therefore, rates of non-adherence derived from studies of mood stabilizers were significantly lower than rates among patients on all three classes of medications, or among those on antipsychotics (*P* < 0.05 or *P* < 0.01), while there were no differences between rates among patients on all classes of medications and those on antipsychotics.

***Demographic correlates of medication non-adherence in BD***

**Reviews:** The evidence that socio-demographic characteristics of patients influence their medication taking behaviour is largely inconsistent among patients with BD[154]. Accordingly, most reviews of the subject have concluded that there is no strong support for anassociation between demographic variables and medication non-adherence in BD[4,6,8,17,22,26]. Though certain demographic characteristics of patients have been associated with non-adherence in some studies of BD, such associations have not been found in others. There is also some discrepancy between reviews about which demographic parameters might be associated with non-adherence in BD; some reviews have concluded that younger age[12,14,22,27,29] and male gender[11,15,22,27] are more likely to be associated with non-adherence,while others have found that being single or living alone[2,3,7,11,15], being less educated[3,12,14,15,17] or belonging to ethnic minorities[3,10,11] were among the most consistent risk factors for non-adherence in BD.

**Studies:** Table 5 list the studies, which have examined the demographic correlates of medication non-adherence in BD. In keeping with the reviews on demographic variables influencing non-adherence in BD, these studies also demonstrate that there is very little to support the notion that demographic attributes of patients have a significant influence on their medication taking behaviour. Firstly, a large number of studies (*n =* 29) have been unable to find an association between medication non-adherence and any demographic variable. Among individual variables young age has often been cited as a correlate of non-adherence in BD[12,14,22,27,29], but the number of studies which have found an association with young age (*n =* 22) was almost similar to those that have been unable to demonstrate such an association (*n =* 19). Studies that have found associations with male gender, single marital status, lower levels of education, unemployment or low socioeconomic status or income were fewer than those unable to find such as association, or those that have found the obverse association. There appeared to be some link with a general “social disadvantage” factor including ethnic minority status, homelessness and dysfunctional family atmospheres, but the aggregate number of studies finding a positive association (*n =* 25) was not substantially different from those finding no such association (*n =* 16).

***Clinical correlates of medication non-adherence in BD***

**Reviews:** The relationship between several clinical features and medication non-adherence has been examined in a number of studies of BD. Clinical characteristics, which have been explored have included overall severity of the illness, severity of manic, depressive and psychotic symptoms as well as variables such as age of onset, duration of illness or episode-length, episode polarity and subtypes of BD. The impact of factors such as cognitive impairment, lack of insight and comorbidity on treatment-adherence has also been examined. The overall conclusion of reviews on the subject is that non-adherence in BD is a complex phenomenon and the association with clinical variables is ambiguous. Not only are the results of such associations inconsistent and equivocal, but the causal direction of any positive associations, *i.e.*, whether the clinical variable in question led to non-adherence or vice-versa, is often unclear[4,8,15,28]. Overall severity of illness in terms of number of episodes, number of hospitalizations or suicidality has been found to be associated with non-adherence in a few studies, but this is not a consistent finding[2-4,6,7,12]. Similarly, severity of manic symptoms have been found to impact adherence negatively quite commonly, though not all studies have found this association[2-4,6,15,22,23]. The influence of depressive or mixed symptoms and psychotic symptoms have not been examined often enough to reach any firm conclusions about their effect on non-adherence in BD[2-4,12,18,27,28]. It is postulated that cognitive impairment may adversely affect adherence in BD, but the evidence for this appears to be derived from only a few studies[2-4,8,14]. The evidence linking other clinical variables such as age of onset, duration of illness or episode-length, polarity and bipolar subtypes with non-adherence in BD is limited[3,8,12]. The adverse effects of comorbid personality disorders and anxiety disorders on adherence in BD has also found mention, though the evidence seems limited to a few studies[2-4,8,15]. In contrast, almost every review on the subject has concurred in finding that the presence of comorbid substance use disorders (SUD) has a significant negative impact on adherence in BD[6,8,12,14,23]. Current rather than past substance abuse is more likely to be associated with non-adherence in BD[3,163-166]. Finally, lack of insight and denial of illness has been consistently found to be associated with non-adherence in BD, though studies finding an association between insight and adherence in BD are still few in number[2,11,12,167,168].

**Studies:** Table 6 include studies examining the clinical correlates of medication non-adherence in BD. As is evident from the two tables there was no evidence of a consistent association with non-adherence for the majority of the clinical variables examined. Certain studies did find positive associations between non-adherence and clinical variables such as early age of onset, shorter durations of illness, greater number of hospitalizations, higher number of total, manic, depressive or mixed episodes, rapid cycling course, bipolar versus unipolar disorders and bipolar I versus bipolar II disorders, polarity of episodes, overall severity of illness and severity of depressive, mixed and psychotic symptoms, family history of psychiatric disorders, comorbid personality disorders and comorbid anxiety or hyperkinetic disorders. However, the number of studies, which were unable to find such associations either equalled or outnumbered those with positive associations. The exceptions to this trend were associations of more severe manic symptoms (21 studies with positive associations and 16 without) and cognitive impairment (6 studies with positive associations and 2 without) with non-adherence in BD. Finally, a clear association with medication non-adherence was evident only in the case of two clinical parameters, that is comorbid SUD and lack of insight, where the number of studies with positive associations far outnumbered the studies without such associations.

***Treatment-related correlates of medication non-adherence in BD***

**Reviews:** Several studies have examined the effects of different classes of medications, the duration of treatment with medications, intensity of treatment, *i.e.*, the number of medications and their doses, and the complexity of medication regimens on medication non-adherence in BD. Reviews of literature have found occasional differences in adherence between some of the second-generation antipsychotics (SGAs), but rates of non-adherence with mood stabilizers and antipsychotics have been largely similar[2]. No differences have been found between older and newer medications; indeed rates of non-adherence in BD appear to have remained unchanged over the years despite the availability of newer medications[4,6,15,17,19]. The influence of duration of treatment has been uncertain with non-adherence occurring both in the early as well as late phases of treatment[4,15,17,22]. The number of medications, higher doses and more complicated medication regimes are all expected to increase the risk of non-adherence, but even this has not been reported consistently[4,10,15,17,18]. The bulk of studies, however, have been about side effects of treatment. Reviews of non-adherence in BD have found a link with side effects among certain studies[3,12,21,23], both for side effects associated with mood stabilizers and antipsychotics[16,181-184]. However, many others have concluded that side effects are often not among the major reasons for non-adherence[2,4,6,14,17]. The latter reviews also agree in finding that it is the fear or concern about side effects that frequently leads to non-adherence, rather than the actual presence of side effects. Inadequate efficacy of medication-treatment has also been proposed as a risk factor for non-adherence in BD, with efficacy in reducing depressive symptoms being particularly important from the patient’s perspective[3,12,23].

**Studies:** Similar to the results of studies examining demographic and illness related correlates of non-adherence in BD, studies examining medication-related variables have also yielded few unequivocal associations. Thus, drug classes, the duration of treatment, greater number or higher doses of medications and more complex medication regimens were associated with non-adherence only in a few studies, while the number of studies without such associations were either equal in number or far greater. A positive association with the presence of side effects was reported in 35 studies; more than a-third of these involved lithium. However, 26 studies did not find a positive association and 17 studies found that fear of side effects than their actual presence had a greater impact on non-adherence. Efficacy of treatment had a positive association with non-adherence, but only among 12 studies. These results are depicted in Table 7.

**DISCUSSION**

Given its chronic, relapsing and remitting nature as well as attendant disability, comorbidity and frequent negative therapeutic outcomes, BD is expected to be characterized by high rates of treatment non-adherence. The existing reviews on medication non-adherence in BD (included in Table 1) support this notion by finding that about 40% to 50% of the patients with BD do not take their medications properly. However most of these reviews are several years old and have included about 25 studies or less in most instances. The current review spanned four decades from 1976 to 2016 and was based on a more comprehensive search of the existing literature on medication non-adherence in BD. It also used somewhat broader selection criteria in an effort to include data from as many studies as possible. This resulted in a much larger list of close to 200 reviews and studies on the subject; 132 of these studies were used derive rates of medication non-adherence in BD. The obvious disadvantage of casting such a broad net was the substantial difference in methodologies across the studies that formed a part of this review. Though this significant heterogeneity did not allow a meta-analysis of the data, the results probably reflected a truer and a more up to date picture of medication non-adherence in BD than some of the existing reviews, simply because of the large number of studies included and the longer period covered by this review.

The results of the review yielded some notable findings about the rate of medication non-adherence in BD. To start with there was a wide variation in rates of non-adherence ranging from 0%-96%, which was more a result of the methodological disparities across studies. Nevertheless, the entire group of studies yielded an average rate of 41.5% and a median rate of 40% for medication non-adherence. When the rates were computed excluding outliers with very high or low rates, the mean rate of non-adherence rose to 43% and the median rate to 41%. These rates were remarkably similar to those found in the majority of previously published reviews (Table 1), which have found rates of non-adherence in BD to vary from 8% to 68% with a mean rate of about 40% and a median rate of 41%-42%. Rates of non-adherence were the highest for studies of patients on treatment with antipsychotics (mean 48%-51%; median 47%-48%) followed by studies of patients on all three classes of medications (mean 45%; median 41%-43.5%). Surprisingly, the rates were significantly lower in studies of patients being treated with mood stabilizers (mean 34%-38%; median 31.5%-34%). It was not exactly clear why this was so, particularly since other studies and reviews have not found rates to differ among different classes of medications[2,5,6,21,22].

However, studies of mood stabilizers mainly included lithium; a significant proportion of them (41%) had been conducted in the 1970s to 1990s; and, the number of studies with very low rates was higher than the other two groups. In direct contrast, studies of patients on antipsychotics were conducted more recently and were based mostly on claims data, which also meant that the sample sizes were very large in many of these studies.

Thus, the overall conclusion from the group of studies included in this review is that between a third to about half of the patients with BD are medication non-adherent. However, there is reason to treat these rates with caution because of the considerable divergence in study designs. Differences in rates of non-adherence across studies usually arise principally from the definition of adherence used, the nature and size of the patient sample included, the setting in which the study is conducted, the duration of assessment and the way non-adherence is estimated[4,15,18,80]. Larger studies with more representative samples and longer durations may be more likely to yield more accurate rates of non-adherence. In this review, about half of the studies had less than 100 patients (48%) while studies with 100-500 patients formed a significant proportion of the total number of studies (39%) Studies with large and more representative samples (naturalistic studies with > 500 patients) were fewer (14%) but the mean rate of 49% obtained from them was higher than the mean rate of 41.5%-43% obtained for the entire group. Studies with longer durations (> 1-10 years) formed 25% of the sample. However, the mean rate of non-adherence (36%) among studies with longer durations was lower than the average rate of 41.5%-43% of the entire group. This was possibly due to fact that the bulk of studies with long durations involved mood stabilizers, a group in which mean rates of non-adherence (34%-38%) were lower than that for other medication classes. Different types of subjective and objective methods are often used to estimate adherence. In the absence of a “gold standard” the use of more than one method is recommended as the next best alternative[2,6,12,14,27]. In this review the majority of studies (54%) had used either self-reports or clinical interviews to estimate adherence; a smaller proportion (11%) used claims data. The low proportion of studies using multiple measures of adherence (29%) could thus cast some doubts on the rates of non-adherence obtained in this review.

A major problem of research in the area of determinants of non-adherence in BD has been the exclusive focus on demographic, illness and treatment related predictors of non-adherence[3,6,13,15,127]. This has been largely driven by the traditional medical model and compliance-based approaches to the problem of non-adherence in BD. As demonstrated in this review, studies examining demographic, illness and treatment related variables (numbering close to 160) far exceeded those that focused on patient-related factors such as attitudes and beliefs about medications, relationship with the clinician, knowledge about the illness and the influence of the wider socio-cultural environment on medication taking in BD. Social and cultural factors are of potential importance and likely to play a major role in determining treatment-adherence in BD[154]. However, despite the large number of studies and the long list of variables examined, the search to identify demographic, illness and treatment related factors associated with non-adherence in BD has yielded little of note. This review found that none of the demographic attributes of patients such as age, gender, marital status, education, employment, income or social disadvantage were consistently linked to medication non-adherence in BD. Among clinical characteristics the presence of comorbid SUD and the absence of insight were the only two factors consisted associated with non-adherence with BD. The severity of manic symptoms appeared to show some association with non-adherence among studies of BD included in this review, as did cognitive impairment in a few studies. Given that about half or more of the patients with BD might have a comorbid SUD, the usefulness of this determinant has been questioned[8]. Lack of insight is expected to adversely affect adherence more so among patients in acute symptomatic phases of mania. However, the role of insight is less certain in other phases such as depression or in the inter-episodic period. Moreover, lack of insight is only one among several influences on non-adherence in BD; therefore, the presence of adequate insight by itself may not be enough to ensure adherence. In accordance with several previous reviews[2,4,6,10,15] medication-related variables such as the types of medications, duration of treatment, greater number of medications, higher doses and complexity of treatment regimens did not demonstrate consistent associations with non-adherence among studies of BD included in this review. Earlier reviews of non-adherence in BD have found a link with side effects of medications[3,12,21,23]. A positive association with the presence of side effects was reported in 35 studies of this review; more than a-third of these involved lithium. At the same time almost an equal number of studies did not find a positive association and many found that fear of side effects than their actual presence had a greater impact on non-adherence. This indicates that side effects are often not among the major reasons for non-adherence in BD and that fear or concern about side effects (an attitudinal variable) may be the more important determinant[2,4,6,17,167].

There could be several reasons for the unequivocal findings regarding clinical and socio-demographic determinants of non-adherence in BD. The simplified and dichotomous approach to examining the association between these parameters and non-adherence in BD has usually ignored the complex relationship between several such variables. For example, the link with manic symptoms could well be related to the lack of insight or cognitive impairment during episodes rather than the severity of symptoms. Moreover, the pathways through which demographic and illness or medication related variables influence could include subjective factors such as attitudes, knowledge or other socio-environmental influences. Therefore, though some of these factors such as comorbid SUD or lack of insight may identify patient groups at higher risk for non-adherence, they cannot identify which of the patients from these high risk groups will go on to develop non-adherence.

Despite being based on a comprehensive search and a much larger number of studies than earlier reviews, the findings of this review were not without their limitations. Many reviews on the management of BD, which mention the problem of non-adherence in passing have not been included. In all likelihood the number of studies on medication non-adherence in BD is larger than the current list of studies, because some studies especially those publications not in English were probably missed. The relative lack of studies from non-Western countries was also a handicap. However, the principal shortcoming was the difficulty of drawing reliable conclusions from studies with such widely disparate methodologies. Nevertheless, it was quite evident that the rate of medication non-adherence in BD was quite high and no different from other chronic psychiatric or medical disorders. The failure of demographic, illness and treatment related factors to predict non-adherence was also not entirely unexpected. However, this emphasizes the importance of other patient orientated factors in determining non-adherence in BD. Research over the last two decades or so has consistently endorsed the significance of several such factors including patients’ attitudes and beliefs about medications, their treatment alliance with the health-care provider, their knowledge and causal beliefs about the illness, the influence of the family, and the role of stigma and treatment-access in determining non-adherence in BD[200]. A patient-centred approach to non-adherence in BD is also in consonance with the current theoretical perspectives on medication-taking behaviour and the emphasis on combining pharmacological and psychosocial strategies to enhance adherence in BD[201]. Therefore, future research which combines some of more consistent clinical and demographic correlates with patient-centred determinants is likely to predict non-adherence in BD with a greater degree of accuracy. Such an approach may also lead to a better understanding of this complex phenomenon and suggest more effective ways to deal with the continuing challenge of medication non-adherence in BD.

**COMMENTS**

***Background***

Previously published reviews on medication non-adherence in bipolar disorder (BD) have estimated rates to vary from around 8% to 68%, with mean rates ranging from 25% to 40% and median rates from 40% to 42%. However, these most of these reviews are based on a relatively small number of studies, are somewhat dated and have not comprehensively searched the existing literature. Given these drawbacks, the present review aimed to conduct a more comprehensive and systematic search for all studies estimating rates of medication non-adherence in BD and/or providing information on demographic, illness and medication related determinants of non-adherence.

***Research frontiers***

Treatment non-adherence in BD has attracted a lot of research attention lately because not only is it common in BD, but it also has a number of negative effects on outcome, and enhancing adherence has proved to be challenging.

***Innovations and breakthroughs***

The current review spanned four decades from 1976 to 2016 and was based on a more comprehensive search of the existing literature on medication non-adherence in BD. This resulted in a much larger list of close to 200 reviews and studies on the subject. Nevertheless, the results endorsed the consensus in existing literature that medication non-adherence is present in a third to about half of the patients with BD. There is also little consensus among earlier reviews regarding the association of clinical, demographic and treatment-related variables with medication non-adherence in BD. The present review clearly demonstrated that demographic and medication-related factors have little influence on medication non-adherence in BD, while among clinical factors only comorbid substance use disorder and absence of insight were clearly linked to non-adherence in BD.

***Applications***

The failure of clinical and demographic factors to predict non-adherence emphasizes the importance of other patient orientated factors in determining non-adherence in BD. Therefore, future research should also focus on patient-centred determinants of medication non-adherence in BD and adherence interventions should emphasize the role of these factors.

***Terminology***

Adherence has been defined as “the extent to which a person’s behaviour, taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider”.

***Peer-review***

The manuscript is well organized and written, the used methodology is rigorous and the conclusions are coherent with the main findings.

**REFERENCES**

1 **Sabate E**. Adherence to long term therapies: evidence for action. Geneva: World Health Organization, 2003

2 **Berk L**, Hallam KT, Colom F, Vieta E, Hasty M, Macneil C, Berk M. Enhancing medication adherence in patients with bipolar disorder. *Hum Psychopharmacol* 2010; **25**: 1-16 [PMID: 20041478 DOI: 10.1002/hup.1081]

3 **Busby KK**, Sajatovic M. REVIEW: Patient, treatment, and systems-level factors in bipolar disorder nonadherence: A summary of the literature. *CNS Neurosci Ther* 2010; **16**: 308-315 [PMID: 21050421 DOI: 10.1111/j.1755-5949.2010.00191.x]

4 **Colom F**, Vieta E, Tacchi MJ, Sánchez-Moreno J, Scott J. Identifying and improving non-adherence in bipolar disorders. *Bipolar Disord* 2005; **7** Suppl 5: 24-31 [PMID: 16225557 DOI: 10.1111/j.1399-5618.2005.00248]

5 **Cochran SD**. Compliance with lithium regimens in the outpatient treatment of bipolar affective disorders. *J Compliance Health Care* 1986; **1**: 153-170

6 **Lingam R**, Scott J. Treatment non-adherence in affective disorders. *Acta Psychiatr Scand* 2002; **105**: 164-172 [PMID: 11939969 DOI: 10.1034/j.1600-0447.2002.1r084]

7 **Perlick DA**, Rosenheck RA, Kaczynski R, Kozma L. Medication non-adherence in bipolar disorder: a patient-centered review of research findings. *Clin Approaches Bipolar Disord* 2004; **3**: 56-64

8 **Basco MR**, Smith J. Faulty decision-making: impact on treatment adherence in bipolar disorder. *Primary Psychiatry* 2009; **16**: 53-58

9 **Jamison KR**, Gerner RH, Goodwin FK. Patient and physician attitudes toward lithium: relationship to compliance. *Arch Gen Psychiatry* 1979; **36**: 866-869 [PMID: 454105 DOI: 10.1001/archpsyc.1979.01780080040011]

10 **Pompili M**, Serafini G, Del Casale A, Rigucci S, Innamorati M, Girardi P, Tatarelli R, Lester D. Improving adherence in mood disorders: the struggle against relapse, recurrence and suicide risk. *Expert Rev Neurother* 2009; **9**: 985-1004 [PMID: 19589049 DOI: 10.1586/ern.09.62]

11 **Rakofsky JJ**, Levy ST, Dunlop BW. Conceptualizing Treatment Nonadherence in Patients with Bipolar Disorder and PTSD. *CNS Spectr* 2011; **16**: 11-20 [PMID: 24725297 DOI: 10.1017/S1092852912000119]

12 **Leclerc E**, Mansur RB, Brietzke E. Determinants of adherence to treatment in bipolar disorder: a comprehensive review. *J Affect Disord* 2013; **149**: 247-252 [PMID: 23489403 DOI: 10.1016/j.jad.2013.01.036]

13 **Scott J**. Cognitive and behavioural approaches to medication adherence. *Adv Psychiatr Treat* 1999; **5**: 338-345 [DOI: 10.1192/apt.5.5.338]

14 **Depp CA**, Moore DJ, Patterson TL, Lebowitz BD, Jeste DV. Psychosocial interventions and medication adherence in bipolar disorder. *Dialogues Clin Neurosci* 2008; **10**: 239-250 [PMID: 18689293]

15 **Crowe M**, Wilson L, Inder M. Patients' reports of the factors influencing medication adherence in bipolar disorder - an integrative review of the literature. *Int J Nurs Stud* 2011; **48**: 894-903 [PMID: 21481391 DOI: 10.1016/j.ijnurstu.2011.03.008]

16 **García S**, Martínez-Cengotitabengoa M, López-Zurbano S, Zorrilla I, López P, Vieta E, González-Pinto A. Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review. *J Clin Psychopharmacol* 2016; **36**: 355-371 [PMID: 27307187 DOI: 10.1097/JCP.0000000000000523]

17 **Berk M**, Berk L, Castle D. A collaborative approach to the treatment alliance in bipolar disorder. *Bipolar Disord* 2004; **6**: 504-518 [PMID: 15541066 DOI: 10.1111/j.1399-5618.2004.00154]

18 **Gaudiano BA**, Weinstock LM, Miller IW. Improving treatment adherence in bipolar disorder: a review of current psychosocial treatment efficacy and recommendations for future treatment development. *Behav Modif* 2008; **32**: 267-301 [PMID: 18391049 DOI: 10.1177/0145445507309023]

19 **Schou M**. The combat of non-compliance during prophylactic lithium treatment. *Acta Psychiatr Scand* 1997; **95**: 361-363 [PMID: 9197898 DOI: 10.1111/j.1600-0447.1997.tb09646]

20 **Van Putten T**. Why do patients with manic-depressive illness stop their lithium? *Compr Psychiatry* 1975; **16**: 179-183 [PMID: 1120419 DOI: 10.1016/0010-440X(75)90064-4]

21 **Jamison KR**, Akiskal HS. Medication compliance in patients with bipolar disorder. *Psychiatr Clin North Am* 1983; **6**: 175-192 [PMID: 6889171]

22 **Goodwin F**, Jamison JK. Manic depressive illness. New York: Oxford University Press, 1990

23 **Foster A**, Sheehan L, Johns L. Promoting treatment adherence in patients with bipolar disorder. *Current Psychiatry* 2011: **10**: 45-52

24 **Schou M**. No help from lithium? About patients who might have been but were not helped by prophylactic lithium treatment. *Compr Psychiatry* 1988; **29**: 83-90 [PMID: 3370972 DOI: 10.1016/0010-440X(88)90001-6]

25 **Guscott R**, Taylor L. Lithium prophylaxis in recurrent affective illness. Efficacy, effectiveness and efficiency. *Br J Psychiatry* 1994; **164**: 741-746 [PMID: 7952980 DOI: 10.1192/bjp.164.6.741]

26 **Scott J**. Psychotherapy for bipolar disorder. *Br J Psychiatry* 1995; **167**: 581-588 [PMID: 8564312 DOI: 10.1192/bjp.167.5.581]

27 **Sajatovic M**, Davies M, Hrouda DR. Enhancement of treatment adherence among patients with bipolar disorder. *Psychiatr Serv* 2004; **55**: 264-269 [PMID: 15001726 DOI: 10.1176/appi.ps.55.3.264]

28 **Byrne N**, Regan C, Livingston G. Adherence to treatment in mood disorders. *Curr Opin Psychiatry* 2006; **19**: 44-49 [PMID: 16612178 DOI: 10.1097/01.yco.0000191501.54034.7c]

29 **Depp CA**, Lebowitz BD. Enhancing medication adherence: in older adults with bipolar disorder. *Psychiatry* (Edgmont) 2007; **4**: 22-32 [PMID: 20711333]

30 **Bech P**, Vendsborg PB, Rafaelsen OJ. Lithium maintenance treatment of manic-melancholic patients: its role in the daily routine. *Acta Psychiatr Scand* 1976; **53**: 70-81 [PMID: 1251757 DOI: 10.1111/j.1600-0447.1976.tb00060.x]

31 **Cochran SD**. Preventing medical noncompliance in the outpatient treatment of bipolar affective disorders. *J Consult Clin Psychol* 1984; **52**: 873-878 [PMID: 6501672 DOI: 10.1037/0022-006X.52.5.873]

32 **Mousavi MEZ**, Mohammadkhani P, Pourshahbaz A, Samiei, M, Rigi Kooteh R. Nonadherence: effective factors in bipolar disorder with previous rehospitalization. *JPCP* 2016; **4**: 255-262 [DOI: 10.18869/acadpub.jpcp.4.4.255]

33 **Roy R**, Jahan M, Kumari S, Chakraborty PK. Reasons for drug non-compliance of psychiatric patients: a centre based study. *JIAAP* 2005; **31**: 24-28

34 **Berger A**, Edelsberg J, Sanders KN, Alvir JM, Mychaskiw MA, Oster G. Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study. *BMC Psychiatry* 2012; **12**: 99 [PMID: 22856540 DOI: 10.1186/1471-244X-12-99]

35 **Cruz LP**, Miranda PM, Vedana KG, Miasso AI. Medication therapy: adherence, knowledge and difficulties of elderly people from bipolar disorder. *Rev Lat Am Enfermagem* 2011; **19**: 944-952 [PMID: 21876947]

36 **Clatworthy J**, Bowskill R, Rank T, Parham R, Horne R. Adherence to medication in bipolar disorder: a qualitative study exploring the role of patients' beliefs about the condition and its treatment. *Bipolar Disord* 2007; **9**: 656-664 [PMID: 17845282 DOI: 10.1111/j.1399-5618.2007.00434]

37 **McCleod MS**, Sharp DM. Precursors of compliance with lithium treatment in affective disorders. *Psychiatr Bull* 2001; **25**: 183-186 [DOI: 10.1192/pb.25.5.183]

38 **Courtney ME**, Acomb JA, Lovatt V. A pharmacy-controlled lithium clinic. *Psychiatr Bull* 1995; **19**: 15-17 [DOI: 10.1192/pb.19.1.15]

39 **Sajatovic M**, Davies MA, Ganocy SJ, Bauer MS, Cassidy KA, Hays RW, Safavi R, Blow FC, Calabrese JR. A comparison of the life goals program and treatment as usual for individuals with bipolar disorder. *Psychiatr Serv* 2009; **60**: 1182-1189 [PMID: 19723732 DOI: 10.1176/ps.2009.60.9.1182]

40 **Sajatovic M**, Biswas K, Kilbourne AK, Fenn H, Williford W, Bauer MS. Factors associated with prospective long-term treatment adherence among individuals with bipolar disorder. *Psychiatr Serv* 2008; **59**: 753-759 [PMID: 18586992 DOI: 10.1176/appi.ps.59.7.753]

41 **Salloum IM**, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. *Arch Gen Psychiatry* 2005; **62**: 37-45 [PMID: 15630071 DOI: 10.1001/archpsyc.62.1.37]

42 **Sylvia LG**, Reilly-Harrington NA, Leon AC, Kansky CI, Calabrese JR, Bowden CL, Ketter TA, Friedman ES, Iosifescu DV, Thase ME, Ostacher MJ, Keyes M, Rabideau D, Nierenberg AA. Medication adherence in a comparative effectiveness trial for bipolar disorder. *Acta Psychiatr Scand* 2014; **129**: 359-365 [PMID: 24117232 DOI: 10.1111/acps.12202]

43 **Dharmendra MS**, Eagles JM. Factors associated with patients' knowledge of and attitudes towards treatment with lithium. *J Affect Disord* 2003; **75**: 29-33 [PMID: 12781347 DOI: 10.1016/S0165-0327(02)00027-7]

44 **Bauer M**, Glenn T, Grof P, Marsh W, Sagduyu K, Alda M, Murray G, Lewitzka U, Schmid R, Haack S, Whybrow PC. The association between concurrent psychotropic medications and self-reported adherence with taking a mood stabilizer in bipolar disorder. *Hum Psychopharmacol* 2010; **25**: 47-54 [PMID: 20033908 DOI: 10.1002/hup.1077]

45 **Bauer M**, Glenn T, Alda M, Sagduyu K, Marsh W, Grof P, Munoz R, Baethge C, Lewitzka U, Pilhatsch M, Bauer R, Whybrow PC. Regularity in daily mood stabilizer dosage taken by patients with bipolar disorder. *Pharmacopsychiatry* 2013; **46**: 163-168 [PMID: 23797414 DOI: 10.1055/s-0033-1343398]

46 **Sajatovic M**, Davies M, Bauer MS, McBride L, Hays RW, Safavi R, Jenkins J. Attitudes regarding the collaborative practice model and treatment adherence among individuals with bipolar disorder. *Compr Psychiatry* 2005; **46**: 272-277 [PMID: 16175758 DOI: 10.1016/j.comppsych.2004.10.007]

47 **Keck PE**, McElroy SL, Strakowski SM, Stanton SP, Kizer DL, Balistreri TM, Bennett JA, Tugrul KC, West SA. Factors associated with pharmacologic noncompliance in patients with mania. *J Clin Psychiatry* 1996; **57**: 292-297 [PMID: 8666570]

48 **Keck PE**, McElroy SL, Strakowski SM, West SA, Sax KW, Hawkins JM, Bourne ML, Haggard P. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. *Am J Psychiatry* 1998; **155**: 646-652 [PMID: 9585716 DOI: 10.1176/ajp.155.5.646]

49 **Strakowski SM**, Keck PE, McElroy SL, West SA, Sax KW, Hawkins JM, Kmetz GF, Upadhyaya VH, Tugrul KC, Bourne ML. Twelve-month outcome after a first hospitalization for affective psychosis. *Arch Gen Psychiatry* 1998; **55**: 49-55 [PMID: 9435760 DOI: 10.1001/archpsyc.55.1.49]

50 **Weiss RD**, Greenfield SF, Najavits LM, Soto JA, Wyner D, Tohen M, Griffin ML. Medication compliance among patients with bipolar disorder and substance use disorder. *J Clin Psychiatry* 1998; **59**: 172-174 [PMID: 9590667 DOI: 10.4088/JCP.v59n0405]

51 **Colom F**, Vieta E, Martínez-Arán A, Reinares M, Benabarre A, Gastó C. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. *J Clin Psychiatry* 2000; **61**: 549-555 [PMID: 10982196 DOI: 10.4088/JCP.v61n0802]

52 **Svarstad BL**, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. *Psychiatr Serv* 2001; **52**: 805-811 [PMID: 11376229 DOI: 10.1176/appi.ps.52.6.805]

53 **Calabrese JR**, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL, Greene PL, Monaghan ET. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. *J Clin Psychiatry* 2000; **61**: 841-850 [PMID: 11105737 DOI: 10.4088/JCP.v61n1106]

54 **Greenhouse WJ**, Meyer B, Johnson SL. Coping and medication adherence in bipolar disorder. *J Affect Disord* 2000; **59**: 237-241 [PMID: 10854641 DOI: 10.1016/S0165-0327(99)00152-4]

55 **Lam DH**, Watkins ER, Hayward P, Bright J, Wright K, Kerr N, Parr-Davis G, Sham P. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. *Arch Gen Psychiatry* 2003; **60**: 145-152 [PMID: 12578431 DOI: 10.1001/archpsyc.60.2.145]

56 **Calabrese JR**, Shelton MD, Rapport DJ, Youngstrom EA, Jackson K, Bilali S, Ganocy SJ, Findling RL. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. *Am J Psychiatry* 2005; **162**: 2152-2161 [PMID: 16263857 DOI: 10.1176/appi.ajp.162.11.2152]

57 **Coletti DJ**, Leigh E, Gallelli KA, Kafantaris V. Patterns of adherence to treatment in adolescents with bipolar disorder. *J Child Adolesc Psychopharmacol* 2005; **15**: 913-917 [PMID: 16379511 DOI: 10.1089/cap.2005.15.913]

58 **Fleck DE**, Keck PE, Corey KB, Strakowski SM. Factors associated with medication adherence in African American and white patients with bipolar disorder. *J Clin Psychiatry* 2005; **66**: 646-652 [PMID: 15889954 DOI: 10.4088/JCP.v66n0517]

59 **Sajatovic M**, Bauer MS, Kilbourne AM, Vertrees JE, Williford W. Self-reported medication treatment adherence among veterans with bipolar disorder. *Psychiatr Serv* 2006; **57**: 56-62 [PMID: 16399963 DOI: 10.1176/appi.ps.57.1.56]

60 **DelBello MP**, Hanseman D, Adler CM, Fleck DE, Strakowski SM. Twelve-month outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. *Am J Psychiatry* 2007; **164**: 582-590 [PMID: 17403971 DOI: 10.1176/ajp.2007.164.4.582]

61 **Johnson FR**, Ozdemir S, Manjunath R, Hauber AB, Burch SP, Thompson TR. Factors that affect adherence to bipolar disorder treatments: a stated-preference approach. *Med Care* 2007; **45**: 545-552 [PMID: 17515782 DOI: 10.1097/MLR.0b013e318040ad90]

62 **Montoya A**, Pérez Sánchez Toledo J, Gilaberte I, González-Pinto A, Haro JM, Vieta E, Tohen M. Patterns of drug treatment for manic episode in the clinical practice. Outcomes of the Spanish sample in the EMBLEM Study. *Actas Esp Psiquiatr* 2007; **35**: 315-322 [PMID: 17885823]

63 **Sajatovic M**, Elhaj O, Youngstrom EA, Bilali SR, Rapport DJ, Ganocy SJ, Calabrese JR. Treatment adherence in individuals with rapid cycling bipolar disorder: results from a clinical-trial setting. *J Clin Psychopharmacol* 2007; **27**: 412-414 [PMID: 17632236 DOI: 10.1097/01.jcp.0000280310.50871.ff]

64 **Shabani A**, Eftekhar M. Non-compliance after first episode of manic or mixed mood state: a 17-months follow-up. *IJPBS* 2007; **1**: 46-49

65 **Strakowski SM**, Tsai SY, Delbello MP, Chen CC, Fleck DE, Adler CM, Arndt S, Amicone J. Outcome following a first manic episode: cross-national US and Taiwan comparison. *Bipolar Disord* 2007; **9**: 820-827 [PMID: 18076531 DOI: 10.1111/j.1399-5618.2007.00411.x]

66 **Baldessarini RJ**, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. *Hum Psychopharmacol* 2008; **23**: 95-105 [PMID: 18058849 DOI: 10.1002/hup.908]

67 **Copeland LA**, Zeber JE, Salloum IM, Pincus HA, Fine MJ, Kilbourne AM. Treatment adherence and illness insight in veterans with bipolar disorder. *J Nerv Ment Dis* 2008; **196**: 16-21 [PMID: 18195637 DOI: 10.1097/NMD.0b013e318160ea00]

68 **Zeber JE**, Copeland LA, Good CB, Fine MJ, Bauer MS, Kilbourne AM. Therapeutic alliance perceptions and medication adherence in patients with bipolar disorder. *J Affect Disord* 2008; **107**: 53-62 [PMID: 17822779 DOI: 10.1016/j.jad.2007.07.026]

69 **Taj F**, Tanwir M, Aly Z, Khowajah AA, Tariq A, Syed FK, Waqar F, Shahzada K. Factors associated with non-adherence among psychiatric patients at a tertiary care hospital, Karachi, Pakistan: a questionnaire based cross-sectional study. *J Pak Med Assoc* 2008; **58**: 432-436 [PMID: 18822640]

70 **Azorin JM**, Aubrun E, Bertsch J, Reed C, Gerard S, Lukasiewicz M. Mixed states vs. pure mania in the French sample of the EMBLEM study: results at baseline and 24 months--European mania in bipolar longitudinal evaluation of medication. *BMC Psychiatry* 2009; **9**: 33 [PMID: 19500417 DOI: 10.1186/1471-244X-9-33]

71 **Clatworthy J**, Bowskill R, Parham R, Rank T, Scott J, Horne R. Understanding medication non-adherence in bipolar disorders using a Necessity-Concerns Framework. *J Affect Disord* 2009; **116**: 51-55 [PMID: 19101038 DOI: 10.1016/j.jad.2008.11.004]

72 **Sajatovic M**, Ignacio RV, West JA, Cassidy KA, Safavi R, Kilbourne AM, Blow FC. Predictors of nonadherence among individuals with bipolar disorder receiving treatment in a community mental health clinic. *Compr Psychiatry* 2009; **50**: 100-107 [PMID: 19216885 DOI: 10.1016/j.comppsych.2008.06.008]

73 **Sharifi A**, Shabani A, Ahmadzad-Asl M. The pattern of adherence in patients with bipolar I disorder an eight weeks study. *IJPBS* 2009; **3**: 39-43

74 **Martinez-Aran A**, Scott J, Colom F, Torrent C, Tabares-Seisdedos R, Daban C, Leboyer M, Henry C, Goodwin GM, Gonzalez-Pinto A, Cruz N, Sanchez-Moreno J, Vieta E. Treatment nonadherence and neurocognitive impairment in bipolar disorder. *J Clin Psychiatry* 2009; **70**: 1017-1023 [PMID: 19497247 DOI: 10.4088/JCP.08m04408]

75 **Mazza M**, Mandelli L, Di Nicola M, Harnic D, Catalano V, Tedeschi D, Martinotti G, Colombo R, Bria P, Serretti A, Janiri L. Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up. *J Affect Disord* 2009; **115**: 27-35 [PMID: 18845344 DOI: 10.1016/j.jad.2008.08.019]

76 **Bates JA**, Whitehead R, Bolge SC, Kim E. Correlates of medication adherence among patients with bipolar disorder: results of the bipolar evaluation of satisfaction and tolerability (BEST) study: a nationwide cross-sectional survey. *Prim Care Companion J Clin Psychiatry* 2010; **12**: [PMID: 21274363 DOI: 10.4088/PCC.09m00883yel]

77 **Devulapalli KK**, Ignacio RV, Weiden P, Cassidy KA, Williams TD, Safavi R, Blow FC, Sajatovic M. Why do persons with bipolar disorder stop their medication? *Psychopharmacol Bull* 2010; **43**: 5-14 [PMID: 21150842]

78 **González-Pinto A**, Reed C, Novick D, Bertsch J, Haro JM. Assessment of medication adherence in a cohort of patients with bipolar disorder. *Pharmacopsychiatry* 2010; **43**: 263-270 [PMID: 20842617 DOI: 10.1055/s-0030-1263169]

79 **Hou R**, Cleak V, Peveler R. Do treatment and illness beliefs influence adherence to medication in patients with bipolar affective disorder? A preliminary cross-sectional study. *Eur Psychiatry* 2010; **25**: 216-219 [PMID: 20005683 DOI: 10.1016/j.eurpsy.2009.09.003]

80 **Jónsdóttir H**, Opjordsmoen S, Birkenaes AB, Engh JA, Ringen PA, Vaskinn A, Aamo TO, Friis S, Andreassen OA. Medication adherence in outpatients with severe mental disorders: relation between self-reports and serum level. *J Clin Psychopharmacol* 2010; **30**: 169-175 [PMID: 20520290 DOI: 10.1097/JCP.0b013e3181d2191e]

81 **Gutiérrez-Rojas L**, Jurado D, Martínez-Ortega JM, Gurpegui M. Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample. *J Affect Disord* 2010; **127**: 77-83 [PMID: 20576292 DOI: 10.1016/j.jad.2010.05.021]

82 **Perlis RH**, Ostacher MJ, Miklowitz DJ, Hay A, Nierenberg AA, Thase ME, Sachs GS. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. *J Clin Psychiatry* 2010; **71**: 296-303 [PMID: 20331931 DOI: 10.4088/JCP.09m05514yel]

83 **Cely EEP**, Fierro M, Pinilla MI. Prevalence and factors associated with non-adherence in drug maintenance treatment in adults with bipolar affective disorder. *Rev Colomb Psiquiatr* 2011; **40**: 85-98 [DOI: 10.1016/S0034-7450(14)601062]

84 **Hong J**, Reed C, Novick D, Haro JM, Aguado J. Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. *Psychiatry Res* 2011; **190**: 110-114 [PMID: 21571375 DOI: 10.1016/j.psychres.2011.04.016]

85 **Savaş HA**, UnalA,Vırıt O. Treatment adherence in bipolar disorder. *JMOOD* 2011; **1**: 95-102 [DOI: 10.5455/jmood.20110827015615]

86 **Sajatovic M**, Micula-Gondek W, Tatsuoka C, Bialko C. The relationship of gender and gender identity to treatment adherence among individuals with bipolar disorder. *Gend Med* 2011; **8**: 261-268 [PMID: 21763217 DOI: 10.1016/j.genm.2011.06.002]

87 **Mahmood KT**, Akram SK, Razzaq UA, Haq IU, Minaa T. Mangement of bipolar disorder (BD) through medication at public sector hospital in Lahore. *J Pharm Sci Res* 2011; **3**: 1491-1498

88 **Barraco A**, Rossi A, Nicolò G. Description of study population and analysis of factors influencing adherence in the observational Italian study "Evaluation of Pharmacotherapy Adherence in Bipolar Disorder" (EPHAR). *CNS Neurosci Ther* 2012; **18**: 110-118 [PMID: 21199448 DOI: 10.1111/j.1755-5949.2010.00225.x}]

89 **Eker F**, Harkın S. Effectiveness of six-week psychoeducation program on adherence of patients with bipolar affective disorder. *J Affect Disord* 2012; **138**: 409-416 [PMID: 22316565 DOI: 10.1016/j.jad.2012.01.004]

90 **Murru A**, Pacchiarotti I, Nivoli AM, Bonnin CM, Patrizi B, Amann B, Vieta E, Colom F. Rates and clinical correlates of treatment non-adherence in schizoaffective bipolar patients. *Acta Psychiatr Scand* 2012; **125**: 412-418 [PMID: 22321052 DOI: 10.1111/j.1600-0447.2012.01837.x]

91 **Miasso AI**, do Carmo BP, Tirapelli CR. [Bipolar affective disorder: pharmacotherapeutic profile and adherence to medication]. *Rev Esc Enferm USP* 2012; **46**: 689-695 [PMID: 22773491 DOI: 10.1590/S0080-62342012000300022]

92 **Sajatovic M**, Levin J, Tatsuoka C, Micula-Gondek W, Fuentes-Casiano E, Bialko CS, Cassidy KA. Six-month outcomes of customized adherence enhancement (CAE) therapy in bipolar disorder. *Bipolar Disord* 2012; **14**: 291-300 [PMID: 22548902 DOI: 10.1111/j.1399-5618.2012.01010.x]

93 **Vieta E**, Azorin JM, Bauer M, Frangou S, Perugi G, Martinez G, Schreiner A. Psychiatrists' perceptions of potential reasons for non- and partial adherence to medication: results of a survey in bipolar disorder from eight European countries. *J Affect Disord* 2012; **143**: 125-130 [PMID: 22840608 DOI: 10.1016/j.jad.2012.05.041]

94 **Sharma S**, Kumar N, Chakraborti S, Sinha S, Kumari S, Gajendragad JM. Prevalence and factors associated with medication compliance in Indian patients suffering from mental disorders. *Trop Doct* 2012; **42**: 28-31 [PMID: 22037517]

95 **Belzeaux R**, Correard N, Boyer L, Etain B, Loftus J, Bellivier F, Bougerol T, Courtet P, Gard S, Kahn JP, Passerieux C, Leboyer M, Henry C, Azorin JM. Depressive residual symptoms are associated with lower adherence to medication in bipolar patients without substance use disorder: results from the FACE-BD cohort. *J Affect Disord* 2013; **151**: 1009-1015 [PMID: 24051101 DOI: 10.1016/j.jad.2013.08.028]

96 **de Souza C**, Vedana KG, Mercedes BP, Miasso AI. Bipolar disorder and medication: adherence, patients' knowledge and serum monitoring of lithium carbonate. *Rev Lat Am Enfermagem* 2013; **21**: 624-631 [PMID: 23797558 DOI: 10.1590/S0104-11692013000200021]

97 **Gibson S**, Brand SL, Burt S, Boden ZV, Benson O. Understanding treatment non-adherence in schizophrenia and bipolar disorder: a survey of what service users do and why. *BMC Psychiatry* 2013; **13**: 153 [PMID: 23714262 DOI: 10.1186/1471-244X-13-153]

98 **Hibdye G**, Dessalegne Y, Debero N, Bekan L, Sintayehu M. Prevalence of drug non adherence and associated factors among patients with bipolar disorder at outpatient unit of Amanuel Hospital, Addis Ababa, Ethiopia, 2013. *J Psychiatry* 2015; **S1**: 003 [DOI: 10.4172/2378-5756.S1-003]

99 **Jónsdóttir H**, Opjordsmoen S, Birkenaes AB, Simonsen C, Engh JA, Ringen PA, Vaskinn A, Friis S, Sundet K, Andreassen OA. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. *Acta Psychiatr Scand* 2013; **127**: 23-33 [PMID: 22900964 DOI: 10.1111/j.1600-0447.2012.01911]

100 **Murru A**, Pacchiarotti I, Amann BL, Nivoli AM, Vieta E, Colom F. Treatment adherence in bipolar I and schizoaffective disorder, bipolar type. *J Affect Disord* 2013; **151**: 1003-1008 [PMID: 24099884 DOI: 10.1016/j.jad.2013.08.026]

101 **Arvilommi P**, Suominen K, Mantere O, Leppämäki S, Valtonen H, Isometsä E. Predictors of adherence to psychopharmacological and psychosocial treatment in bipolar I or II disorders - an 18-month prospective study. *J Affect Disord* 2014; **155**: 110-117 [PMID: 24262639 DOI: 10.1016/j.jad.2013.10.032]

102 **Kassis IT**, Ghuloum S, Mousa H, Bener A. Treatment non-compliance of psychiatric patients and associated factors: are patients satisfied from their psychiatrist? *Br J Med Med Res* 2014; **4**: 785-796 [DOI: 10.9734/BJMMR/2014/6127]

103 **Ghaffari-Nejad A**, Mashayekhi A, Mazhari S, Ghayoumi A. Factors associated with drug non-adherence after discharge among patients with mood disorders hospitalized in Shahid Beheshti Hospital in Kerman: a prospective study. *Zahedan J Res Med Sci* 2015; **17**: e968 [DOI: 10.5812/zjrms.17(4)2015.968]

104 **Hajda M**, Kamaradova D, Latalova K, Prasko J, Ociskova M, Mainerova B. Self-stigma, treatment adherence, and medication discontinuation in patients with bipolar disorders in remission – a cross sectional study. *Act Nerv Super Rediviva* 2015; **57**: 6-11

105 **Ibrahim AW**, Pindar SK, Yerima MM, Rabbebe IB, Shehu S, Garkuwa HA, Bashir IY, Wakil MA, Yahya SJ. Medication-related factors of non adherence among patients with schizophrenia and bipolar disorder: Outcome of a cross-sectional survey in Maiduguri, North-eastern Nigeria. *Journal of Neuroscience and Behavioral Health* 2015; **7**: 31-39 [DOI: 10.5897/JNBH2015.0128]

106 **Levin JB**, Tatsuoka C, Cassidy KA, Aebi ME, Sajatovic M. Trajectories of medication attitudes and adherence behavior change in non-adherent bipolar patients. *Compr Psychiatry* 2015; **58**: 29-36 [PMID: 25617964 DOI: 10.1016/j.comppsych.2014.11.023]

107 **Mert DG**, Turgut NH, Kelleci M, Semiz M. Perspectives on reasons of medication nonadherence in psychiatric patients. *Patient Prefer Adherence* 2015; **9**: 87-93 [PMID: 25609930 DOI: 10.2147/PPA.S75013]

108 **Azadforouz S**, Shabani A, Nohesara S, Ahmadzad-Asl M. Non-Compliance and Related Factors in Patients With Bipolar I Disorder: A Six Month Follow-Up Study. *Iran J Psychiatry Behav Sci* 2016; **10**: e2448 [PMID: 27803718 DOI: 10.17795/ijpbs-2448]

109 **Connelly CE**, Davenport YB, Nurnberger JI. Adherence to treatment regimen in a lithium carbonate clinic. *Arch Gen Psychiatry* 1982; **39**: 585-588 [PMID: 6807256 DOI: 10.1001/archpsyc.1982.04290050057011]

110 **Connelly CE**. Compliance with outpatient lithium therapy. *Perspect Psychiatr Care* 1984; **22**: 44-50 [PMID: 6570862 DOI: 10.1111/j.1744-6163.1984.tb00203.x]

111 **Danion JM**, Neunreuther C, Krieger-Finance F, Imbs JL, Singer L. Compliance with long-term lithium treatment in major affective disorders. *Pharmacopsychiatry* 1987; **20**: 230-231 [PMID: 3671494 DOI: 10.1055/s-2007-1017111]

112 **Aagaard J**, Vestergaard P, Maarbjerg K. Adherence to lithium prophylaxis: II. Multivariate analysis of clinical, social, and psychosocial predictors of nonadherence. *Pharmacopsychiatry* 1988; **21**: 166-170 [PMID: 3205885 DOI: 10.1055/s-2007-1014670]

113 **Maarbjerg K**, Aagaard J, Vestergaard P. Adherence to lithium prophylaxis: I. Clinical predictors and patient's reasons for nonadherence. *Pharmacopsychiatry* 1988; **21**: 121-125 [PMID: 3406049 DOI: 10.1055/s-2007-1014662]

114 **Cochran SD**, Gitlin MJ. Attitudinal correlates of lithium compliance in bipolar affective disorders. *J Nerv Ment Dis* 1988; **176**: 457-464 [PMID: 3404137 DOI: 10.1097/00005053-198808000-00001]

115 **Vestergaard P**, Schou M. Prospective studies on a lithium cohort. 1. General features. *Acta Psychiatr Scand* 1988; **78**: 421-426 [PMID: 3227961 DOI: 10.1111/j.1600-0447.1988.tb06361.x]

116 **Lenzi A**, Lazzerini F, Placidi GF, Cassano GB, Akiskal HS. Predictors of compliance with lithium and carbamazepine regimens in the long-term treatment of recurrent mood and related psychotic disorders. *Pharmacopsychiatry* 1989; **22**: 34-37 [PMID: 2652160 DOI: 10.1055/s-2007-1014574]

117 **Nilsson A**, Axelsson R. Factors associated with discontinuation of long-term lithium treatment. *Acta Psychiatr Scand* 1989; **80**: 221-230 [PMID: 2510458 DOI: 10.1111/j.1600-0447.1989]

118 **Aagaard J**, Vestergaard P. Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study. *J Affect Disord* 1990; **18**: 259-266 [PMID: 2140378 DOI: 10.1016/0165-0327(90)90077-L]

119 **Lee S**, Wing YK, Wong KC. Knowledge and compliance towards lithium therapy among Chinese psychiatric patients in Hong Kong. *Aust N Z J Psychiatry* 1992; **26**: 444-449 [PMID: 1417630 DOI: 10.3109/00048679209072068]

120 **Berghöfer A**, Kossmann B, Müller-Oerlinghausen B. Course of illness and pattern of recurrences in patients with affective disorders during long-term lithium prophylaxis: a retrospective analysis over 15 years. *Acta Psychiatr Scand* 1996; **93**: 349-354 [PMID: 8792904 DOI: 10.1111/j.1600-0447.1996.tb10659.x]

121 **Keck PE**, McElroy SL, Strakowski SM, Bourne ML, West SA. Compliance with maintenance treatment in bipolar disorder. *Psychopharmacol Bull* 1997; **33**: 87-91 [PMID: 9133756]

122 **Maj M**, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. *Am J Psychiatry* 1998; **155**: 30-35 [PMID: 9433335 DOI: 10.1176/ajp.155.1.30]

123 **Schumann C**, Lenz G, Berghöfer A, Müller-Oerlinghausen B. Non-adherence with long-term prophylaxis: a 6-year naturalistic follow-up study of affectively ill patients. *Psychiatry Res* 1999; **89**: 247-257 [PMID: 10708271 DOI: 10.1016/S0165-1781(99)00108-0]

124 **Wong SS**, Lee S, Wat KH. A preliminary communication of an insight scale in the assessment of lithium non-adherence among Chinese patients in Hong Kong. *J Affect Disord* 1999; **55**: 241-244 [PMID: 10628895 DOI: 10.1016/S0165-0327(99)00003-8]

125 **Licht RW**, Vestergaard P, Rasmussen NA, Jepsen K, Brodersen A, Hansen PE. A lithium clinic for bipolar patients: 2-year outcome of the first 148 patients. *Acta Psychiatr Scand* 2001; **104**: 387-390 [PMID: 11722321 DOI: 10.1111/j.1600-0447.2001.00389.x]

126 **Scott J**. Using Health Belief Models to understand the efficacy-effectiveness gap for mood stabilizer treatments. *Neuropsychobiology* 2002; **46** Suppl 1: 13-15 [PMID: 12571427 DOI: 10.1159/000068022]

127 **Scott J**, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. *J Clin Psychiatry* 2002; **63**: 384-390 [PMID: 12019661 DOI: 10.4088/JCP.v63n0502]

128 **Scott J**, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. *Am J Psychiatry* 2002; **159**: 1927-1929 [PMID: 12411230 DOI: 10.1176/appi.ajp.159.11.1927]

129 **Pope M**, Scott J. Do clinicians understand why individuals stop taking lithium? *J Affect Disord* 2003; **74**: 287-291 [PMID: 12738048 DOI: 10.1016/S0165-0327(02)00341-5]

130 **Bowden CL**, Collins MA, McElroy SL, Calabrese JR, Swann AC, Weisler RH, Wozniak PJ. Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo. *Neuropsychopharmacology* 2005; **30**: 1932-1939 [PMID: 15956987 DOI: 10.1038/sj.npp.1300788]

131 **Patel NC**, DelBello MP, Keck PE, Strakowski SM. Ethnic differences in maintenance antipsychotic prescription among adolescents with bipolar disorder. *J Child Adolesc Psychopharmacol* 2005; **15**: 938-946 [PMID: 16379514 DOI: 10.1089/cap.2005.15.938]

132 **Gonzalez-Pinto A**, Mosquera F, Alonso M, López P, Ramírez F, Vieta E, Baldessarini RJ. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. *Bipolar Disord* 2006; **8**: 618-624 [PMID: 17042834 DOI: 10.1111/j.1399-5618.2006.00368.x]

133 **Drotar D**, Greenley RN, Demeter CA, McNamara NK, Stansbrey RJ, Calabrese JR, Stange J, Vijay P, Findling RL. Adherence to pharmacological treatment for juvenile bipolar disorder. *J Am Acad Child Adolesc Psychiatry* 2007; **46**: 831-839 [PMID: 17581447 DOI: 10.1097/chi.0b013e31805c7421]

134 **Kessing LV**, Søndergård L, Kvist K, Andersen PK. Adherence to lithium in naturalistic settings: results from a nationwide pharmacoepidemiological study. *Bipolar Disord* 2007; **9**: 730-736 [PMID: 17988363 DOI: 10.1111/j.1399-5618.2007.00405.x]

135 **Manwani SG**, Szilagyi KA, Zablotsky B, Hennen J, Griffin ML, Weiss RD. Adherence to pharmacotherapy in bipolar disorder patients with and without co-occurring substance use disorders. *J Clin Psychiatry* 2007; **68**: 1172-1176 [PMID: 17854240 DOI: 10.4088/JCP.v68n0802]

136 **Rosa AR**, Marco M, Fachel JM, Kapczinski F, Stein AT, Barros HM. Correlation between drug treatment adherence and lithium treatment attitudes and knowledge by bipolar patients. *Prog Neuropsychopharmacol Biol Psychiatry* 2007; **31**: 217-224 [PMID: 16982121 DOI: 10.1016/j.pnpbp.2006.08.007]

137 **Sajatovic M**, Valenstein M, Blow F, Ganoczy D, Ignacio R. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. *Psychiatr Serv* 2007; **58**: 855-863 [PMID: 17535948 DOI: 10.1176/ps.2007.58.6.855]

138 **Baldessarini R**, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. *Psychiatr Serv* 2008; **59**: 1175-1183 [PMID: 18832504 DOI: 10.1176/appi.ps.59.10.1175]

139 **Vega P**, Alonso M, Alberich S, Barbeito S, de Azúa SR, Ugarte A. Why do bipolar men not comply with treatment? The Spanish CIBERSAM data. *Eur J Psychiatr* 2009; **23** (Suppl): 63-69

140 **Scott J**, Colom F, Pope M, Reinares M, Vieta E. The prognostic role of perceived criticism, medication adherence and family knowledge in bipolar disorders. *J Affect Disord* 2012; **142**: 72-76 [PMID: 22944191 DOI: 10.1016/j.jad.2012.04.005]

141 **Col SE**, Caykoylu A, Karakas Ugurlu G, Ugurlu M. Factors affecting treatment compliance in patients with bipolar I disorder during prophylaxis: a study from Turkey. *Gen Hosp Psychiatry* 2014; **36**: 208-213 [PMID: 24359677 DOI: 10.1016/j.genhosppsych.2013.11.006]

142 **Keck PE**, McElroy SL, Strakowski SM, Balistreri TM, Kizer DI, West SA. Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. *J Clin Psychiatry* 1996; **57**: 147-151 [PMID: 8601549]

143 **Sajatovic M**, Valenstein M, Blow FC, Ganoczy D, Ignacio RV. Treatment adherence with antipsychotic medications in bipolar disorder. *Bipolar Disord* 2006; **8**: 232-241 [PMID: 16696824 DOI: 10.1111/j.1399-5618.2006.00314.x]

144 **Sajatovic M**, Blow FC, Kales HC, Valenstein M, Ganoczy D, Ignacio RV. Age comparison of treatment adherence with antipsychotic medications among individuals with bipolar disorder. *Int J Geriatr Psychiatry* 2007; **22**: 992-998 [PMID: 17323327 DOI: 10.1002/gps.1777]

145 **Hassan M**, Lage MJ. Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. *Am J Health Syst Pharm* 2009; **66**: 358-365 [PMID: 19202045 DOI: 10.2146/ajhp080374]

146 **Lage MJ**, Hassan MK. The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study. *Ann Gen Psychiatry* 2009; **8**: 7 [PMID: 19226463 DOI: 10.1186/1744-859X-8-7]

147 **Lang K**, Korn J, Muser E, Choi JC, Abouzaid S, Menzin J. Predictors of medication nonadherence and hospitalization in Medicaid patients with bipolar I disorder given long-acting or oral antipsychotics. *J Med Econ* 2011; **14**: 217-226 [PMID: 21370989 DOI: 10.3111/13696998.2011.562265]

148 **Rascati KL**, Richards KM, Ott CA, Goddard AW, Stafkey-Mailey D, Alvir J, Sanders KN, Mychaskiw M. Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder. *Psychiatr Serv* 2011; **62**: 1032-1040 [PMID: 21885581 DOI: 10.1176/appi.ps.62.9.1032]

149 **Stephenson JJ**, Tunceli O, Gu T, Eisenberg D, Panish J, Crivera C, Dirani R. Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians' perceptions of adherence vs. pharmacy claims. *Int J Clin Pract* 2012; **66**: 565-573 [PMID: 22574724 DOI: 10.1111/j.1742-1241.2012.02918.x]

150 **Montes JM**, Maurino J, de Dios C, Medina E. Suboptimal treatment adherence in bipolar disorder: impact on clinical outcomes and functioning. *Patient Prefer Adherence* 2013; **7**: 89-94 [PMID: 23378745 DOI: 10.2147/PPA.S39290]

151 **Kutzelnigg A**, Kopeinig M, Chen CK, Fábián A, Pujol-Luna MG, Shin YC, Treuer T, D'yachkova Y, Deix C, Kasper S, Doby D. Compliance as a stable function in the treatment course of bipolar disorder in patients stabilized on olanzapine: results from a 24-month observational study. *Int J Bipolar Disord* 2014; **2**: 13 [PMID: 25360398 DOI: 10.1186/s40345-014-0013-x]

152 **Sajatovic M**, Ng-Mak D, Solem CT, Lin FJ, Rajagopalan K, Loebel A. Dosing patterns and medication adherence in bipolar disorder patients treated with lurasidone: a US retrospective claims database analysis. *Ther Adv Psychopharmacol* 2016; **6**: 355-368 [PMID: 28008349 DOI: 10.1177/2045125316672135]

153 **Bauer R**, Glenn T, Alda M, Sagduyu K, Marsh W, Grof P, Munoz R, Murray G, Ritter P, Lewitzka U, Severus E, Whybrow PC, Bauer M. Antidepressant dosage taken by patients with bipolar disorder: factors associated with irregularity. *Int J Bipolar Disord* 2013; **1**: 26 [PMID: 25505689 DOI: 10.1186/2194-7511-1-26]

154 **Ragesh G**, Ameer Hamza A, & Santosh K. Chaturvedi SK. Sociocultural determinants of treatment adherence in bipolar disorders: a review of recent trends. *Int J Ment Health* 2016; **9**: 285-292 [DOI: 10.1080/17542863.2016.1196716]

155 **Revicki DA**, Hanlon J, Martin S, Gyulai L, Nassir Ghaemi S, Lynch F, Mannix S, Kleinman L. Patient-based utilities for bipolar disorder-related health states. *J Affect Disord* 2005; **87**: 203-210 [PMID: 16005983 DOI: 10.1016/j.jad.2005.03.017]

156 **Kleindienst N**, Greil W. Are illness concepts a powerful predictor of adherence to prophylactic treatment in bipolar disorder? *J Clin Psychiatry* 2004; **65**: 966-974 [PMID: 15291686]

157 **Yen CF**, Chen CS, Ko CH, Yeh ML, Yang SJ, Yen JY, Huang CF, Wu CC. Relationships between insight and medication adherence in outpatients with schizophrenia and bipolar disorder: prospective study. *Psychiatry Clin Neurosci* 2005; **59**: 403-409 [PMID: 16048445 DOI: 10.1111/j.1440-1819.2005.01392.x]

158 **Frank E**, Prien RF, Kupfer DJ, Alberts L. Implications of noncompliance on research in affective disorders. *Psychopharmacol Bull* 1985; **21**: 37-42 [PMID: 3983336]

159 **Lehmann SW**, Rabins PV. Factors related to hospitalization in elderly manic patients with early and late-onset bipolar disorder. *Int J Geriatr Psychiatry* 2006; **21**: 1060-1064 [PMID: 16955445 DOI: 10.1002/gps.1607]

160 **Rosa AR**, Andreazza AC, Sanchez-Moreno J, Gazalle FK, Santin, A, Stein A. Validation of the Portuguese version of the Lithium Attitudes Questionnaire (LAQ) in bipolar patients treated with lithium: cross-over study. Clin Pract Epidemiol Ment Health 2006; 2: 32 [DOI: 10.1186/1745-0179-2-32]

161 **Jose TT**, Bhaduri A, Mathew B. A study of the factors associated with compliance or non- compliance to lithium therapy among the patients with bipolar affective disorder. *Nurs J India* 2003; **91**: 9-11

162 **Sajatovic M**, Levin J, Fuentes-Casiano E, Cassidy KA, Tatsuoka C, Jenkins JH. Illness experience and reasons for nonadherence among individuals with bipolar disorder who are poorly adherent with medication. *Compr Psychiatry* 2011; **52**: 280-287 [PMID: 21497222 DOI: 10.1016/j.comppsych.2010.07.002]

163 **Salloum IM**, Thase ME. Impact of substance abuse on the course and treatment of bipolar disorder. *Bipolar Disord* 2000; **2**: 269-280 [PMID: 11249805 DOI: 10.1034/j.1399-5618.2000.20308.x]

164 **Sherwood Brown E**, Suppes T, Adinoff B, Rajan Thomas N. Drug abuse and bipolar disorder: comorbidity or misdiagnosis? *J Affect Disord* 2001; **65**: 105-115 [PMID: 11356233 DOI: 10.1016/S0165-0327(00)00169-5]

165 **Cerullo MA**, Strakowski SM. The prevalence and significance of substance use disorders in bipolar type I and II disorder. *Subst Abuse Treat Prev Policy* 2007; **2**: 29 [PMID: 17908301 DOI: 10.1186/1747-597X-2-29]

166 **Peselow ED**. Adherence with respect to medication management. *Primary Psychiatry* 2007. Available from: URL: http://primarypsychiatry.com/adherence-with-respect-to-medication-management/

167 **Prasko J**, Ociskova M, Kamaradova D, Sedlackova Z, Cerna M, Mainerova B, Sandoval A. Bipolar affective disorder and psychoeducation. *Neuro Endocrinol Lett* 2013; **34**: 83-96 [PMID: 23645303]

168 **Gianfrancesco FD**, Sajatovic M, Rajagopalan K, Wang RH. The association between treatment adherence and antipsychotic dose among individuals with bipolar disorder. *Int Clin Psychopharmacol* 2008; **23**: 305-316 [PMID: 18854718 DOI: 10.1097/YIC.0b013e32830b0f88]

169 **Johnson RE**, McFarland BH. Lithium use and discontinuation in a health maintenance organization. *Am J Psychiatry* 1996; **153**: 993-1000 [PMID: 8678195 DOI: 10.1176/ajp.153.8.993]

170 **Sajatovic M**, Levin JB, Sams J, Cassidy KA, Akagi K, Aebi ME, Ramirez LF, Safren SA, Tatsuoka C. Symptom severity, self-reported adherence, and electronic pill monitoring in poorly adherent patients with bipolar disorder. *Bipolar Disord* 2015; **17**: 653-661 [PMID: 26529124 DOI: 10.1111/bdi.12326]

171 **Miklowitz DJ**, Simoneau TL, George EL, Richards JA, Kalbag A, Sachs-Ericsson N, Suddath R. Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy. *Biol Psychiatry* 2000; **48**: 582-592 [PMID: 11018229 DOI: 10.1016/S0006-3223(00)00931-8]

172 **Miklowitz DJ**, George EL, Richards JA, Simoneau TL, Suddath RL. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. *Arch Gen Psychiatry* 2003; **60**: 904-912 [PMID: 12963672 DOI: 10.1001/archpsyc.60.9.904]

173 **Gaudiano BA**, Miller IW. Patients' expectancies, the alliance in pharmacotherapy, and treatment outcomes in bipolar disorder. *J Consult Clin Psychol* 2006; **74**: 671-676 [PMID: 16881774 DOI: 10.1037/0022-006X.74.4.671]

174 **Miklowitz DJ**. Longitudinal outcome and medication noncompliance among manic patients with and without mood-incongruent psychotic features. *J Nerv Ment Dis* 1992; **180**: 703-711 [PMID: 1359003 DOI: 10.1097/00005053-199211000-00004]

175 **Depp CA**, Cain AE, Palmer BW, Moore DJ, Eyler LT, Lebowitz BD, Patterson TL, Jeste DV. Assessment of medication management ability in middle-aged and older adults with bipolar disorder. *J Clin Psychopharmacol* 2008; **28**: 225-229 [PMID: 18344736 DOI: 10.1097/JCP.0b013e318166dfed]

176 **Novick D**, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study. *BMC Psychiatry* 2015; **15**: 189 [PMID: 26239486 DOI: 10.1186/s12888-015-0560-4]

177 **Darling CA**, Olmstead SB, Lund VE, Fairclough JF. Bipolar disorder: medication adherence and life contentment. *Arch Psychiatr Nurs* 2008; **22**: 113-126 [PMID: 18505693 DOI: 10.1016/j.apnu.2008.02.004]

178 **van Rossum I**, Boomsma M, Tenback D, Reed C, van Os J. Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis. *J Nerv Ment Dis* 2009; **197**: 35-40 [PMID: 19155808 DOI: 10.1097/NMD.0b013e31819292a6]

179 **Teter CJ**, Falone AE, Bakaian AM, Tu C, Ongür D, Weiss RD. Medication adherence and attitudes in patients with bipolar disorder and current versus past substance use disorder. *Psychiatry Res* 2011; **190**: 253-258 [PMID: 21696830 DOI: 10.1016/j.psychres.2011.05.042]

180 **Zarate CA**. Antipsychotic drug side effect issues in bipolar manic patients. *J Clin Psychiatry* 2000; **61** Suppl 8: 52-61; discussion 62-63 [PMID: 10811244]

181 **Berk M**, Berk L. Mood stabilizers and treatment adherence in bipolar disorder: addressing adverse events. *Ann Clin Psychiatry* 2003; **15**: 217-224 [PMID: 14971867 DOI: 10.1023/B: ACLI.0000008175.32403.8e]

182 **Mago R**, Borra D, Mahajan R. Adverse effects and nonadherence with mood stabilizers. *Journal of Mood Disorders* 2013; **3** (Suppl. 1): S4-S6

183 **Mago R**, Borra D, Mahajan R. Role of adverse effects in medication nonadherence in bipolar disorder. *Harv Rev Psychiatry* 2014; **22**: 363-366 [PMID: 25377611 DOI: 10.1097/HRP.0000000000000017]

184 **Gianfrancesco F**, Pesa J, Wang RH. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine. *J Manag Care Pharm* 2005; **11**: 220-230 [PMID: 15804206 DOI: 10.18553/jmcp.2005.11.3.220]

185 **Gianfrancesco FD**, Rajagopalan K, Sajatovic M, Wang RH. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. *J Clin Psychiatry* 2006; **67**: 222-232 [PMID: 16566617 DOI: 10.4088/JCP.v67n0208]

186 **Hassan M**, Madhavan SS, Kalsekar ID, Makela EH, Rajagopalan K, Islam S, Kavookjian J, Miller LA. Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder. *Ann Pharmacother* 2007; **41**: 1812-1818 [PMID: 17925501 DOI: 10.1345/aph.1K205]

187 **Gianfrancesco FD**, Sajatovic M, Tafesse E, Wang RH. Association between antipsychotic combination therapy and treatment adherence among individuals with bipolar disorder. *Ann Clin Psychiatry* 2009; **21**: 3-16 [PMID: 19239828]

188 **Vestergaard P**, Amdisen A. Patient attitudes towards lithium. *Acta Psychiatr Scand* 1983; **67**: 8-12 [PMID: 6846037 DOI: 10.1111/j.1600-0447.1983.tb00325.x]

189 **Gitlin MJ**, Cochran SD, Jamison KR. Maintenance lithium treatment: side effects and compliance. *J Clin Psychiatry* 1989; **50**: 127-131 [PMID: 2925600]

190 **Lewis L**. Patient perspectives on the diagnosis, treatment, and management of bipolar disorder. *Bipolar Disord* 2005; **7** (Suppl 1): 33-37 [DOI: 10.1111/j.1399-5618.2005.00192.x]

191 **Mączka G**, Siwek M, Skalski M, Grabski B, Dudek D. Patients’ and doctors’ attitudes towards bipolar disorder – do we share our beliefs? *Archives of Psychiatry and Psychotherapy* 2010; **2**: 43-50

192 **Wang Y**, Henning M. Bipolar disorder and medical adherence: A Chinese perspective. *Asian J Psychiatr* 2010; **3**: 7-11 [PMID: 23051130 DOI: 10.1016/j.ajp.2009.11.003]

193 **Miasso AI**, Cassiani SH, Pedrão LJ. [Affective bipolar disorder and ambivalence in relation to the drug treatment: analyzing the causal conditions]. *Rev Esc Enferm USP* 2011; **45**: 433-441 [PMID: 21655795 DOI: 10.1590/S0080-62342011000200019]

194 **Morselli PL**, Elgie R. GAMIAN-Europe/BEAM survey I--global analysis of a patient questionnaire circulated to 3450 members of 12 European advocacy groups operating in the field of mood disorders. *Bipolar Disord* 2003; **5**: 265-278 [PMID: 12895204 DOI: 10.1034/j.1399-5618.2003.00037.x]

195 **Morselli PL**, Elgie R, Cesana BM. GAMIAN-Europe/BEAM survey II: cross-national analysis of unemployment, family history, treatment satisfaction and impact of the bipolar disorder on life style. *Bipolar Disord* 2004; **6**: 487-497 [PMID: 15541064 DOI: 10.1111/j.1399-5618.2004.00160.x]

196 **Scott J**. Predicting medication non-adherence in severe affective disorders. *Acta Neuropsychiatr* 2000; **12**: 128-130 [PMID: 26975270 DOI: 10.1017/S0924270800035584]

197 **Scott J**, Tacchi MJ. A pilot study of concordance therapy for individuals with bipolar disorders who are non-adherent with lithium prophylaxis. *Bipolar Disord* 2002; **4**: 386-392 [PMID: 12519098 DOI: 10.1034/j.1399-5618.2002.02242.x]

198 **Sajatovic M**, Jenkins JH, Cassidy KA, Muzina DJ. Medication treatment perceptions, concerns and expectations among depressed individuals with Type I Bipolar Disorder. *J Affect Disord* 2009; **115**: 360-366 [PMID: 18996600 DOI: 10.1016/j.jad.2008.10.002]

199 **Kriegshauser K**, Sajatovic M, Jenkins JH, Cassidy KA, Muzina D, Fattal O, Smith D, Singer B. Gender differences in subjective experience and treatment of bipolar disorder. *J Nerv Ment Dis* 2010; **198**: 370-372 [PMID: 20458200 DOI: 10.1097/NMD.0b013e3181da8ef7]

200 **Chakrabarti S**. Treatment-adherence in bipolar disorder: A patient-centred approach. *World J Psychiatry* 2016; **6**: 399-409 [PMID: 28078204 DOI: 10.5498/wjp.v6.i4.399]

201 **MacDonald L**, Chapman S, Syrett M, Bowskill R, Horne R. Improving medication adherence in bipolar disorder: A systematic review and meta-analysis of 30 years of intervention trials. *J Affect Disord* 2016; **194**: 202-221 [PMID: 26851552 DOI: 10.1016/j.jad.2016.01.002]

**P-Reviewer:** Specchia ML, Tang Y **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Specialty type:** Medicine, research and experimental

**Country of origin:** India

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**Table1 Rates of medication non-adherence in bipolar disorder: Reviews**

|  |  |  |
| --- | --- | --- |
| **Ref.** | **Review based on** | **Non-adherence rates** |
| Van Putten[20], 1975 | 7 studies | 20%-30% (only lithium) |
| Jamison and Akiskal[21], 1983 | 10 studies | 33%-50% (only lithium) |
| Cochran[5], 1986 | 13 studies from 1966-1986 | 9%-57% (only lithium) |
| Goodwin and Jamison[22], 1990 | 50 studies | 18%-53% (only lithium) |
| Lingam and Scott[6], 2002 | 3 studies and 1 review | 20%-66%, median 41% |
| Perlick *et al*[7], 2004 | 25 papersfrom 1979-2004 | 23%-68%, median 42% |
| Colom *et al*[4], 2005 | 6 studies | 20%-64%, mean 25% |
| Gaudiano *et al*[18], 2008 | 3 reviews | 20%-60%, mean 40% |
| Basco and Smith[8], 2009 | 9 studies | 8%-64% |
| Busby and Sajatovic[3], 2010 | 6 studies | 20%-60% |
| Foster *et al*[23], 2011 | 7 studies | 21%-50% |
| Leclerc *et al*[12], 2013 | 27 studies(rates derived from 6 studies) | 12%-64% |
| Garcia *et al*[16], 2016 | 9 studies | 23%-60% (only antipsychotics) |

Other reviews have also estimated non-adherence rates to be in the range of 20%-68% with a median rate of 41%-42% in BD including Schou[24] (1988), [Guscott and](https://www.ncbi.nlm.nih.gov/pubmed/?term=Guscott%20R%5BAuthor%5D&cauthor=true&cauthor_uid=7952980) [Taylor[25] (1994), Scott[26] (1995), Schou[19] (1997),](https://www.ncbi.nlm.nih.gov/pubmed/?term=Taylor%20L%5BAuthor%5D&cauthor=true&cauthor_uid=7952980)Berk *et al*[17] (2004), Sajatovic *et al*[27] (2004), Byrne *et al*[28] (2006), [Depp](https://www.ncbi.nlm.nih.gov/pubmed/?term=Depp%20CA%5BAuthor%5D&cauthor=true&cauthor_uid=20711333) and Lebowitz[29] (2007), Depp *et al*[14] (2008), Pompili *et al*[10] (2009), Crowe *et al*[15] (2011) and Rakofsky *et al*[11] (2011). BD: Bipolar disorder.

**Table 2 Rates of medication non-adherence in bipolar disorder: Studies of all classes of medications**

|  |  |  |
| --- | --- | --- |
| **Ref.** | **Study** | **Non-adherence rates** |
| Keck *et al*[47], 1996a | *n =* 101; duration-past month; clinical interview and serum levels | 64% fully or partially non-adherent |
| Keck *et al*[48], 1998  | *n =* 134; duration - 12 mo; clinical interview  | 53% fully or partially non-adherent |
| Stratkowski *et al*[49], 1998  | *n =* 109 (83 with BD); duration - 12 mo; clinical interviews  | 59% fully or partially non-adherent |
| Weiss *et al*[50], 1998 | *n =* 44 with BD and SUD; cross-sectional study; clinical interviews  | 79% fully or partially non-adherent (35% took medications less than 67% of the time) |
| Colom *et al*[51], 2000  | *n =* 200; duration 2 yr; clinical interviews with patients and relatives and serum levels for mood stabilizers | 40% fully or partially non-adherent |
| Svarstad *et al*[52], 2001 | *n =* 67; duration 12 mo; retrospective claims data  | 33% irregular use |
| Calabrese *et al*[53], 2000  | *n =* 324 with RCBD; duration - 6 mo; clinical interview  | 34% |
| Greenhouse *et al*[54], 2000  |  *n =* 32: duration - 1 wk; self-report | 25% |
| Lam *et al*[55], 2003  | *n =* 52; duration - 6 mo; serum levels and self-reports | Serum levels - 7%-22%; self-report - 12%-33% |
| Calabrese *et al*[56], 2005 | *n =* 254 with RCBD; duration - 30 mo; clinical interview | 20%-28% |
| Coletti *et al*[57], 2005 | *n =* 38 adolescents; duration - 1 mo; parent reports | 66% fully or partially non-adherent |
| Fleck *et al*[58], 2005 | *n =* 50; cross-sectional study; visual analogue scale  |  52% fully or partially non-adherent |
| Roy *et al*[33], 2005  | *n =* 100 (42 with BD); cross-sectional study; clinical interview | 91% |
| Sajatovic *et al*[46], 2005  | *n =* 52; duration - 3 mo; self-reports and DAI-10 | 12% |
| Sajatovic *et al*[59], 2006a  | *n =* 323; cross-sectional study; clinical interview | 36% partially or fully non-adherent |
| Clatworthy *et al*[36], 2007  | *n =* 16; cross-sectional study; self-report-qualitative data  | 81% |
| DelBello *et al*[60], 2007 | *n =* 71 adolescents; duration 12 mo; clinical interviews  | 65% fully or partially non-adherent |
| Johnson *et al*[61], 2007  | *n =* 469; cross-sectional study; web-based survey; self-report | 30% |
| Montoya *et al*[62], 2007  | *n =* 312; cross-sectional study; clinical interviews  | 40% fully or partially non-adherent |
| Sajatovic *et al*[63], 2007 c  | *n =* 205 with RCBD; duration - 6 mo; clinical interview | 20% |
| Shabani and Eftekhar[64], 2007  | *n =* 22; duration - 17 mo; clinical interview | 38% |
| Stratkowski *et al*[65], 2007  | *n =* 96 (US) and 46 (Taiwan); duration – 1yr (Taiwan) to 8 yr (US); clinical interviews | 21% (Taiwan) - 41% (US) followed up without full treatment adherence |
| Baldessarini *et al*[66], 2008a  | *n =* 429; duration -last 10 days; self-report | 34% (psychiatrists rated 6%-18% as non-adherent) |
| Copeland *et al*[67], 2008  | *n =* 435; duration - past 4 d; self-report of missed dose and self-report-MMAS | 27% on missed dose and 46% on MMAS |
| Sajatovic *et al*[40], 2008 | *n =* 302; duration - 3 yr; clinical interview | 12% |
| Zeber *et al*[68], 2008 | *n =* 435; cross-sectional study; self-report and MMAS | Overall 30%; 23% (self-report) to 46% (MMAS) |
| Taj *et al*[69], 2008  | *n =* 23; cross-sectional study; clinical interviews | 26% |
| Azorin *et al*[70], 2009 | *n =* 766; duration 2 yr; clinical interview | At baseline - 44% (pure mania) - 50% (mixed mania); at 2 yr - 8% (pure mania) - 16% (mixed mania) |
| Clatworthy *et al*[71], 2009  | *n =* 223; cross-sectional study; self-report - MARS | 30% |
| Martinez-Aran *et al*[74],2009  | *n =* 103; cross-sectional study; clinical interviews with patients and relatives and serum levels for mood stabilizers | 41% |
| Mazza *et al*[75],2009 | *n =* 131 (94 with BD); duration - 12 mo; serum levels and relatives’ reports | 22% |
| Sajatovic *et al*[72], 2009a  | *n =* 140; cross-sectional study; self-report-TRQ | 19% |
| Sajatovic *et al*[39],2009b  | *N =* 164: duration - 12 mo; self-report | 19% |
| Sharifi *et al*[73],2009 | *n =* 76; duration - 8 wk; clinical interview  | 29% |
| Bates *et al*[76],2010 | *n =* 1052; cross-sectional study; web-based survey; self-report -MMAS  | 49.5% |
| Devulapalli *et al*[77], 2010  | *n =* 140; duration - past month; self-report | 19% |
| Gonzalez-Pinto *et al*[78],2010 | *n =* 1831; duration - 24 mo; clinical interview | 23% |
| Hou *et al*[79], 2010  | *n =* 35; cross-sectional study; self-report -MMAS | 54% |
| Jonsdottir *et al*[80],2010 | *n =* 280 (114 with BD); duration- past week; self-report,MARS-5, serum levels | Serum levels - 34%; self-report - 16% |
| Gutiérrez-Rojas *et al*[81], 2010  | *n =* 108; cross-sectional study; clinical interviews with patients and relatives and serum levels for mood stabilizers | 17% |
| Perlis *et al*[82],2010 | *n =* 3640; duration - 12 mo; self-reports and clinical interviews | 54% fully or partially non-adherent (24% non-adherent on 20% or more study visits)  |
| Cely *et al*[83], 2011 | *n =* 124; cross-sectional study; self-report-MMAS  | 30% |
| Cruz *et al*[35], 2011  | *n =* 17 elderly subjects; cross-sectional study; self-report-MMAS  | 88% |
| Hong *et al*[84], 2011 | *n =*1341; duration - 21 mo; clinical interview | 24% |
| Savas *et al*[85],2011  | *n =* 147; duration - 12 mo; self-report | 27% |
| Sajatovic *et al*[86], 2011b  | n= 140; duration - 1 mo; TRQ | 18% |
| Mahmood *et al*[87], 2011  | *n =* 40; duration - 1 mo; clinical interview | 62% |
| Barraco *et al*[88],2012  | *n =* 650; duration - 12 mo; self-report-SMAQ and DAI-10 | 60% at baseline; 31% at 9 mo; 33% at 12 mo |
| Eker and Harkin[89], 2012  | *N =* 71; duration - 6 wk; ANT, self-report-MARS, TOS  | 60%-61% at baseline; 13%-76% at 6wk |
| Murru *et al*[90], 2012  | *n =* 76 schizoaffective disorder-bipolar type; duration - 10 yr; partly retrospective based on clinical interviews with patients and families and serum levels | 41% |
| Miasso *et al*[91], 2012 | *n =* 101; cross-sectional study; self-report-MMAS | 63% |
| Sajatovic *et al*[92], 2012  | *n =* 43; duration - 6 mo; self-report-TRQ, MMAS; Pill counts | TRQ - 48%-51% at baseline; 21%-25% at 6 mo - Pill counts - 58% at baseline |
| Vieta *et al*[93], 2012  | *n =* 2448 psychiatrists; duration-3 mo; questionnaire survey | 57% patients rated fully or partially non-adherent  |
| Sharma *et al*[94], 2012 | *n =* 127; cross-sectional study; self-report | 40% |
| Belzeaux *et al*[95], 2013  | *n =* 382; cross-sectional study; self-report - MARS and clinical interviews | 25% |
| de Souza *et al*[96], 2013  | *n =* 36 cross-sectional study; self-report - MMAS | 78% |
| Gibson *et al*[97], 2013  | *n =* 24; cross-sectional study; self-report | 50%-77% fully or partially non adherent |
| Hibdye *et al*[98], 2013 | *n =* 410; cross-sectional study; self-report - MMAS | 51% |
| Jonsdottir *et al*[99], 2013 | *n =* 255 (109 with BD); duration- past week; self-report, serum levels | 42% fully or partially non-adherent  |
| Murru *et al*[100], 2013  | schizoaffective disorder-bipolar type (*n =* 75) and BD (*n =* 151); duration - 10 yr; partly retrospective based on clinical interviews with patients and families and serum levels | BD - 33%; schizoaffective disorder-bipolar type - 44% |
| Arvilommi *et al*[101], 2014  | *n =* 168; duration 18 mo; clinical interview | > 50% non-adherent |
| Kassis *et al*[102], 2014  | *N =* 76: cross-sectional study; questionnaire based | 55% |
| Ghaffari-Nejad *et al*[103], 2015 | *n =* 123; duration-6 mo; DAI = 10 | 61% fully or partially non-adherent |
| Hajda *et al*[104], 2015  | *n =* 33; cross-sectional study; self-report - DAI-10 | 58% |
| Ibrahim *et al*[105], 2015  | *n =* 358 (177 with BD); cross-sectional study; self-report-MMAS-8  | 46% |
| Levin *et al*[106], 2015  |  *n =* 65; duration-3 mo; self-report-TRQ | 32%-59% at baseline; 10% - 40% at 3 mo |
| Mert *et al*[107], 2015  | *n =* 68; duration - 6 mo; self-reports; relatives’ reports, medical records  | 45% |
| Azadforouz *et al*[108], 2016  | *n =* 47; duration-6 mo; clinical interview | 36% |
| Mousavi *et al*[32], 2016  | *n =* 73 with BD and psychotic symptoms; cross-sectional study; clinical interviews  | 96% |

ANT: Attitudes towards neuroleptic treatment; BD: Bipolar disorder; CRS: Compliance rating scale; DAI-10: Drug Attitude Inventory-10 item version; MARS: Medication Adherence Report Scale (MARS-5-five item version); MMAS: Morisky Medication Adherence Scale (MMAS-8-8 item version); MPR: Medication possession ration; RBC: Red blood cells; RCBD: Rapid cycling bipolar disorder; RSM: Reasons for Stopping Medication’ questionnaire; ROMI: Rating of Medication Influences Scale; SGA: Second generation antipsychotics; SMAQ: Simplified Medication Adherence Questionnaire; SUD: Substance use disorders; SRTAB: Self-reported Treatment Adherence Behaviours; TOS: Treatment Observation Form; TRQ: Tablet Routines Questionnaire.

**Table 3 Rates of medication non-adherence in bipolar disorder: Studies of mood stabilizers**

|  |  |  |
| --- | --- | --- |
| **Ref.** | **Study** | **Non-adherence rates** |
| Bech *et al*[30], 1976 | *n =* 76 on lithium (49 with BD); duration - 2 yr; retrospective case record data and serum levels  | 24% |
| Jamison *et al*[9], 1979  | *n =* 47 on lithium; cross-sectional study; self-report and psychiatrists’ estimations | Patients - 47% non-adherent; psychiatrists -35% non-adherent |
| Connelly *et al*[109], 1982  | *n =* 48 on lithium; duration - 9 mo; serum levels and > 75% clinic attendance | 25% |
| Connelly *et al*[110], 1984 | *n =* 75 on lithium; duration - 6 mo; serum levels and > 75% clinic attendance | 33% |
| Cochran[31], 1984  | *n =* 28 on lithium; duration - 6 mo; self-report; case notes; clinical interview and serum levels | 93% had major or minor non-cadherence |
| Danion *et al*[111], 1987  | *n =* 73 on lithium (36 with BD); duration- 2 yr; retrospective psychiatric assessments and serum levels | 56% - subjective 19%; objective 56% |
| Aagaard *et al*[112], 1988Maarbjerg *et al*[113], 1988 | *n =*133 on lithium (47 with BD); duration - 6 mo; clinical interview | 23% |
| Cochran and Gitlin[114], 1988  | *n =* 48 on lithium (43 with BD); cross-sectional study; patient questionnaires  | 46% fully or partially non-adherent  |
| Vestergaard and Schou[115],1988  | *n =* 480 on lithium (187 with BD); duration - 7 yr; medical records based on serum levels and clinical interviews  | 50% in first 6 mo; 25% per year during the first 2 yr; 10% per year after 4-5 yr |
| Lenzi *et al*[116], 1989  | *n =* 67 women on lithium or carbamazepine; duration - 8 mo; self-report and serum levels | 45% |
| Nilsson and Axelsson[117], 1989 | *n =* 64 with mood disorders on lithium; duration - 7 yr; serum levels and medical records | 25% |
| Aagaard and Vestergaard[118],1990  | *n =* 133 on lithium (61 with BD); duration - 2 yr; clinical interview | 42% |
| Courtney *et al*[38], 1995  | *n =* 15 on lithium; cross-sectional study; serum levels | 0 |
| Lee *et al*[119], 1992  | *n =* 50 on lithium; duration 12 mo; self-report; clinical interview; serum levels | 30% |
| Berghofer *et al*[120], 1996 | *n =* 86 (55 with BD) on lithium; retrospective follow-up over a mean of 8.9 yr based on clinical interview and serum levels | 24% |
| Keck *et al*[121], 1997  | *n =* 140 on mood stabilizers; duration - 12 mo; clinical interview  | 51% fully or partially non-adherent |
| Maj *et al*[122], 1998 | *n =* 402 on lithium; duration - 5 yr; clinical interview and serum levels | 28% |
| Schuman *et al*[123], 1999  | *n =* 75 (31 with BD) on lithium; duration-6 yr; retrospective medical records based on interviews and serum levels | 55% |
| Wong *et al*[124], 1999  | *n =* 80 with mood disorders on lithium (60 with BD cross-sectional study; self-reports; clinical interviews; serum levels  | 27.5% |
| Licht *et al*[125], 2001  | *n =* 148 on mood stabilizers (132 on lithium): duration 24 mo; retrospective analysis of treatment charts, serum levels and clinical interviews | 20% |
| McCleod and Sharp[37], 2001  | *n =* 30 on lithium; cross-sectional study; self-reports, clinical ratings and serum levels  | 0 |
| Svarstad *et al*[52], 2001  | *n =* 53 on lithium; duration 12 mo; retrospective claims data  | 26% irregular use |
| Scott[126], 2002  | *n =* 98 (85 with BD) on mood stabilizers; cross-sectional study; self-reports-ROMI and TRQ  | 30% partially adherent |
| Scott and Pope[127], 2002a  | *n =* 98 on mood stabilizers (78 with BD); duration- 24 mo; TRQ and serum levels | partial non-adherence - 47% over 2 yr; 32%over past month; 27% over past week; full non-adherence - 20% over 2 yr |
| Scott and Pope[128], 2002b  | *n =* 98 on mood stabilizers (78 with BD); duration - 18 mo; TRQ and serum levels | TRQ - 32% partial adherence; serum levels - 36% |
| Dharmendra and Eagles[43], 2003  | *n =* 411; duration - 3 yr; retrospective study based on self-reports and serum levels  | 15% |
| Pope and Scott[129], 2003  | *n =* 72 on lithium (61 with BD); duration - 2 yr; self-report-RSM | 46% |
| Bowden *et al*[130], 2005  | *n =* 372 on lithium or valproate; duration - 52 wk; clinical interview | 54%-75% premature discontinuations |
| Calabrese *et al*[56], 2005  | *n =* 254 with RCBD on lithium or valproate; duration 20 mo; clinical interviews and serum levels  | 10%-28% |
| Patel *et al*[131], 2005  | *n =* 32 adolescents on mood stabilizers; duration - 12 mo; clinical interviews andmedical records | Treatment time without full adherence in 47% |
| Salloum *et al*[41], 2005  |  *n =* 59 with BD and alcohol dependence on lithium or lithium and valproate; duration - 24 wk; self-report and serum levels | 13%-14% |
| Gonzalez-Pinto *et al*[132], 2006  | *n =* 72; duration - 10 yr; clinical interviews and serum levels | 22% |
| Drotar *et al*[133], 2007  | *n =* 107 adolescents; on lithium and valproate; duration - 20 wk; serum levels, pill counts, self/parent report and clinical interview | 16%-34% (average 17%) non-adherent on various measures |
| Kessing *et al*[134], 2007  | *n =* 14277 on lithium; duration 6 yr; nation-wide register and pharmacy data | 25% stopped lithium within 45 d |
| Manwani *et al*[135], 2007 | *n =* 115 on mood stabilizers; duration - 10 mo; clinical interview | 34% lifetime adherence in those with SUD 17% in those without SUD  |
| Rosa *et al*[136], 2007  | *n =* 106; cross-sectional study; self-report-MARS and serum and RBC levels  | 14% (based on levels) 33% (based on MARS) |
| Sajatovic *et al*[137], 2007a | *n =* 44,637 on mood stabilizers; duration - 3 mo or more; retrospective claims data-MPR based | 46% partially or fully non-adherent; took medications less than 50%-80% of the time |
| Baldessarini *et al*[138], 2008b  | *n =* 2197 on single mood stabilizers; duration - 12 mo; national health plan claims data; MPR based | 72% took medications less than 80% of the time |
| Vega *et al*[139], 2009  | *n =* 72 on lithium; duration - 5 yr; clinical interviews and serum levels  | 8% (women)-39% (men) |
| Bauer *et al*[44], 2010 | *n =* 312 on mood stabilizers; duration - 6 mo; self-report | 11% partially or fully non-adherent |
| Sajatovic *et al*[86], 2011b  | *n =* 136; duration - 1 mo; self-report-TRQ | 18% in the past week or month |
| Scott *et al*[140], 2012  | *n =* 81 on mood stabilizers; cross-sectional study; self-report -TRQ  | 26% - past month |
| Bauer *et al*[45], 2013a  | *n =* 206 on mood stabilizers; duration 100 days; self-report | 14% mean percentof days of missing doses |
| Arvilommi *et al*[101], 2014  | *n =* 168 on mood stabilizers; duration 18 mo; clinical interview | 40% fully or partially non-adherent |
| Sylvia *et al*[42], 2014 | *n =* 283 on lithium; duration - 6 mo; self-report-TRQ | 4.5%-7% reported missing at least30% of their medications in the past week |
| Col *et al*[141], 2014 | *n =* 78 on mood stabilizers; cross-sectional study; self-report-MARS  | 42% |

ANT: Attitudes towards neuroleptic treatment; BD: Bipolar disorder; CRS: Compliance Rating Scale; DAI-10: Drug Attitude Inventory-10 item version; MARS: Medication Adherence Report Scale (MARS-5-five item version); MMAS: Morisky Medication Adherence Scale (MMAS-8-8 item version); MPR: Medication possession ration; RBC: Red blood cells; RCBD: Rapid cycling bipolar disorder; RSM: Reasons for Stopping Medication’ questionnaire; ROMI: Rating of Medication Influences Scale; SGA: Second generation antipsychotics; SMAQ: Simplified Medication Adherence Questionnaire; SUD: Substance use disorders; SRTAB: Self-reported Treatment Adherence Behaviours; TOS: Treatment Observation Form; TRQ: Tablet Routines Questionnaire.

**Table 4 Rates of medication non-adherence in bipolar disorder: studies of antipsychotics and antidepressants**

|  |  |  |
| --- | --- | --- |
| **Ref.** | **Study** | **Non-adherence rates** |
|  |
| **Antipsychotics** |
| Keck *et al*[142], 1996b | *n =* 77 on antipsychotics; duration - 6 mo; clinical interview | 32% |
| Svarstad *et al*[52], 2001 | *n =* 56 on antipsychotics; duration 12 mo; retrospective claims data  | 23% irregular use |
| Patel *et al*[131], 2005 | *n =* 32 adolescents on antipsychotics; duration - 12 mo; clinical interviews and medical records | Treatment time without full adherence in 44% |
| Sajatovic *et al*[143], 2006b |  *n =* 32993 on antipsychotics; duration - 3 mo or more; retrospective claims data-MPR based | 48% partially or fully non-adherent; took antipsychotics less than 50%-80% of the time |
| Sajatovic *et al*[144], 2007b |  *n =* 73964 on antipsychotics; duration - 3 mo or more; retrospective claims data-MPR based  | 39% among those > 60 yr and 50% in those < 60 yr took antipsychotics less than 50%-80% of the time |
| Hassan and Lage[145], 2009 | *n =* 1973 on antipsychotics; duration - 12 mo; retrospective claims based data -MPR based | 56% took antipsychotics less than 50% of the time and 73% less than 75% of the time |
| Lage and Hasan[146], 2009 | *n =* 7,769 on antipsychotics; duration- 12 mo; retrospective claims data-MPR based | 62% took antipsychotics less than 50% of the time and 79% less than 75% of the time |
| Lang *et al*[147], 2011 | *n =* 9410 on antipsychotics; duration - 12 mo; retrospective claims data-MPR based | 60% took antipsychotics less than 80% of the time |
| Rascati *et al*[148], 2011 | *n =* 2446 on SGAs; duration - 18 mo; retrospective claims data-MPR based | 42% took antipsychotics less than 80% of the time |
| Berger *et al*[34], 2012 | *n =* 84 on SGAs: Duration-6 mo; retrospective claims data-MPR and CMG based | 85% took antipsychotics less than 80% of times (50% according to CMGs)  |
| Stephenson *et al*[149], 2012 | *n =* 162 patients with BD on SGAs and 153 physicians; duration - 12 mo; retrospective claims data and physician survey | 57% with low-moderate adherence; physicians overestimated adherence in 67% patients |
| Montes *et al*[150], 2013 | *n =* 303; cross-sectional study; self-reports- DAI-10 and MMAS, CRS | 69% |
| Kutzelnigg *et al*[151], 2014 | Olanzapine alone or in combination with mood stabilizers; *n =* 891 at entry; 657 at 2 yr; clinical interview | 33% at baseline; 20% at 2 yr |
| Arvilommi *et al*[101], 2014 | *n =*168 on SGAs; duration 18 mo; clinical interview | 46% fully or partially non-adherent |
| Sajatovic *et al*[152], 2016 | *n =* 1114 on lurasidone; duration- 27 mo; retrospective claims data-MPR based | 67%took lurasidone less than 80% of the time  |
| **Antidepressants** |
| Svarstad *et al*[52], 2001 | *n =* 22 on antidepressants; duration 12 mo; retrospective claims data  | 27% irregular use |
| Bauer *et al*[153], 2013b | *n =* 144 on antidepressants; duration - daily for 100 d; self-report | 19% (missing/changing doses) to 41% (drug holidays) |

ANT: Attitudes towards neuroleptic treatment; BD: Bipolar disorder; CMG: Cumulative medication gaps; CRS: Compliance Rating Scale; DAI-10: Drug Attitude Inventory-10 item version; MARS: Medication Adherence Report Scale (MARS-5-five item version); MMAS: Morisky Medication Adherence Scale (MMAS-8-8 item version); MPR: Medication possession ration; RBC: Red blood cells; RCBD: Rapid cycling bipolar disorder; RSM: Reasons for Stopping Medication’ questionnaire; ROMI: Rating of Medication Influences Scale; SGA: Second generation antipsychotics; SMAQ: Simplified Medication Adherence Questionnaire; SUD: substance use disorders; SRTAB: Self-reported Treatment Adherence Behaviours; TOS: Treatment Observation Form; TRQ: Tablet Routines Questionnaire.

**Table 5 Studies of demographic correlates of medication non-adherence in bipolar disorder**

|  |  |  |  |
| --- | --- | --- | --- |
| **Demographic correlates**  | **Studies with positive associations** | **Studies without positive associations** | **Others** |
| Any demographic variable |  | Jamison *et al*[9], 1979; Aagaard and Vestergaard[118], 1990; Maj *et al*[122], 1998; Schuman *et al*[123], 1999; Colom *et al*[51], 2000; Licht *et al*[125], 2001; Scott [126], 2002; Scott and Pope[127], 2002a; Kliendienst and Griel[156], 2004; Revicki *et a*l[155], 2005; Yen *et al*[157], 2005; Sajatovic *et al*[59], 2006a; Sajatovic *et al*[40], 2008; Taj *et al*[69], 2008; Sajatovic *et al*[72], 2009a; Clatworthy *et al*[71], 2009; Martinez-Aran *et al*[74], 2009; Sharifi *et al*[73], 2009; Gonzalez-Pinto *et al*[78], 2010; Cely *et al*[83], 2011; Murru *et al*[90], 2012; Bauer *et al*[45], 2013a; Bauer *et al*[153], 2013b; Jonsdottir *et al*[99], 2013; Col *et al*[141], 2014; Sylvia *et al*[42], 2014; Ghaffari-Nejad *et al*[103], 2015; Levin *et al*[106], 2015; Mert *et al*[107], 2015 |  |
|  Young age | Frank *et al*[158], 1985; [Kleindienst and](http://www.ncbi.nlm.nih.gov/pubmed/?term=Kleindienst%20N%5BAuthor%5D&cauthor=true&cauthor_uid=15291686) [Greil[156],2004; Sajatovic *et al*[143], 2006b;](http://www.ncbi.nlm.nih.gov/pubmed/?term=Greil%20W%5BAuthor%5D&cauthor=true&cauthor_uid=15291686) Sajatovic *et al*[137], 2007a; Sajatovic *et al*[144], 2007b; Johnson *et al*[61], 2007; Baldessarini *et al*[66], 2008a; Baldessarini *et al*[138], 2008b; Copeland *et al*[67], 2008; Mazza *et al*[75], 2009; Bates *et al*[76], 2010; Bauer *et al*[44], 2010; Hou *et al*[79], 2010; Perlis *et al*[82], 2010; Lang *et al*[147], 2011; Savas *et al*[85], 2011; Barraco *et al*[88], 2012; Montes *et al*[150], 2013; Hajda *et al*[104], 2015; Levin *et al*[106], 2015; Mousavi *et al*[32], 2016 | Danion *et al*[111], 1987; Maarbjerg *et al*[113], 1988; Lenzi *et al*[116], 1989; Colom *et al*[51], 2000; Licht *et al*[125], 2001; Coletti *et al*[57], 2005; Gonzalez-Pinto *et al*[132], 2006; Drotar *et al*[133], 2007; Rosa *et al*[136], 2007; Sajatovic *et al*[144], 2007b; Sajatovic *et al*[63], 2007 c; Zeber *et al*[68], 2008; Savas *et al*[85], 2011; Belzeaux *et al*[95], 2013; Hibdye *et al*[98], 2013; Murru *et al*[100], 2013; Kutzelnigg *et al*[151], 2014; Azadforouz *et al*[108], 2016 | Both young and old age- Kessing *et al*[134], 2007Old age - Lehman and Rabins[159], 2006; Rascati *et al*[148],2011; Sharma *et al*[94], 2012 |
| Male gender | Frank *et al*[158],1985; Aagaard *et al*[112], 1988; Vestergaard and Schou[115], 1988; McCleod and Sharp[37], 2001; Gonzalez-Pinto *et al*[132], 2006; Drotar *et al*[133], 2007; Vega *et al*[139], 2009; Savas *et al*[85], 2011; Mousavi *et al*[32], 2016 | Danion *et al*[111], 1987; Maarbjerg *et al*[113], 1988; Licht *et al*[125], 2001; Gonzalez-Pinto *et al*[132], 2006; Rosa *et al*[160], 2006; Rosa *et al*[136], 2007; [Sajatovic *et al*[143], 2006b;](http://www.ncbi.nlm.nih.gov/pubmed/?term=Greil%20W%5BAuthor%5D&cauthor=true&cauthor_uid=15291686) Sajatovic *et al*[137], 2007a; Sajatovic *et al*[144], 2007b; Sajatovic *et al*[63], 2007c; Johnson *et al*[61], 2007; Baldessarini *et al*[66], 2008a; Baldessarini *et al*[138], 2008b; Mazza *et al*[75], 2009; Bauer *et al*[44], 2010; Hou *et al*[79], 2010; Perlis *et al*[82], 2010; Rascati *et al*[148],2011; Sajatovic *et al*[86], 2011b; Barraco *et al*[88], 2012; Sharma *et al*[94], 2012; Hibdye *et al*[98], 2013; Montes *et al*[150], 2013; Kutzelnigg *et al*[151], 2014; Hajda *et al*[104], 2015; Azadforouz *et al*[108], 2016 | Female gender - Keck *et al*[142], 1996b; Keck *et al*[121], 1997; Jose *et al*[161],2003; Sajatovic *et al*[46], 2005; Kessing *et al*[134], 2007; Copeland *et al*[67], 2008; Zeber *et al*[68], 2008; Bates *et al*[76], 2010; Belzeaux *et al*[95], 2013; Murru *et al*[100], 2013  |
| Not married | Frank *et al*[158],1985; Aagaard *et al*[112], 1988; Connelly *et al*[109], 1982; Connelly *et al*[110], 1984; Gonzalez-Pinto *et al*[132], 2006; Sajatovic *et al*[137], 2007a; Vega *et al*[139], 2009; Perlis *et al*[82],2010; Sajatovic *et al*[162],2011a; Hajda *et al*[104], 2015 | Lenzi *et al*[116], 1989; Licht *et al*[125], 2001; Gonzalez-Pinto *et al*[132], 2006; Sajatovic *et al*[144], 2007b; Sajatovic *et al*[63], 2007c; Zeber *et al*[68], 2008; Mazza *et al*[75], 2009; Bauer *et al*[44], 2010; Hou *et al*[79], 2010; Savas *et al*[85], 2011; Barraco *et al*[88], 2012; Sharma *et al*[94], 2012; Belzeaux *et al*[95], 2013; Hibdye *et al*[98], 2013; Murru *et al*[100], 2013; Azadforouz *et al*[108], 2016; Mousavi *et al*[32], 2016 |  |
| Poorly educated | Frank *et al*[158],1985; Connelly *et al*[110], 1984; Danion *et al*[111], 1987; Johnson *et al*[61], 2007; Sajatovic *et al*[63], 2007c; Bates *et al*[76], 2010; Savas *et al*[85], 2011; Hajda *et al*[104], 2015; Mousavi *et al*[32], 2016 | Aagaard *et al*[112], 1988; Maarbjerg *et al*[113], 1988; Gonzalez-Pinto *et al*[132], 2006; Zeber *et al*[68], 2008; Bauer *et al*[44], 2010; Hou *et al*[79], 2010; Perlis *et al*[82], 2010; Sharma *et al*[94], 2012; Belzeaux *et al*[95], 2013; Hibdye *et al*[98], 2013 |  |
| Unemployment | Aagaard *et al*[112], 1988; Perlis *et al*[82], 2010; Hibdye *et al*[98], 2013; Montes *et al*[150], 2013 | Sajatovic *et al*[63], 2007c; Bauer *et al*[44], 2010; Hou *et al*[79], 2010; Perlis *et al*[82], 2010; Savas *et al*[85], 2011; Barraco *et al*[88], 2012; Sharma *et al*[94], 2012; Murru *et al*[100], 2013; Hajda *et al*[104], 2015 |  |
| Low socioeconomic status or income | DelBello *et al*[60], 2007; Perlis *et al*[82], 2010  | Aagaard *et al*[112], 1988; Maarbjerg *et al*[113], 1988; Lenzi *et al*[116], 1989; Aagaard and Vestergaard[118],1990; Johnson *et al*[61], 2007; Zeber *et al*[68], 2008; Savas *et al*[85], 2011; Sharma *et al*[94], 2012 |  |
| Ethnic minority status | Keck *et al*[121],1997; Stratkowski *et al*[49], 1998; [Greil, [156] 2004; Sajatovic *et al*[143], 2006b;](http://www.ncbi.nlm.nih.gov/pubmed/?term=Greil%20W%5BAuthor%5D&cauthor=true&cauthor_uid=15291686) Sajatovic *et al*[137], 2007a; Sajatovic *et al*[144], 2007b; Sajatovic *et al*[63], 2007c; Johnson *et al*[61], 2007; Copeland *et al*[67], 2008; Zeber *et al*[68], 2008; Perlis *et al*[82], 2010; Rascati *et al*[148],2011; Sajatovic *et a*l[162] 2011a; Sajatovic *et al*[92], 2012 | Fleck *et al*[58], 2005; Patel *et al*[131], 2005; Drotar *et al*[133], 2007; Baldessarini *et al*[66], 2008a; Baldessarini *et al*[138], 2008b; Bates *et al*[76], 2010; Hibdye *et al*[98], 2013; Kutzelnigg *et al*[151], 2014 |  |
| Living alone/homeless | Lenzi *et al*[116], 1989; [Greil, [156] 2004; Sajatovic *et al*[143], 2006b;](http://www.ncbi.nlm.nih.gov/pubmed/?term=Greil%20W%5BAuthor%5D&cauthor=true&cauthor_uid=15291686) Sajatovic *et al*[137], 2007a; Sajatovic *et al*[144], 2007b | Zeber *et al*[68], 2008; Montes *et al*[150], 2013; Murru *et al*[100], 2013; Hajda *et al*[104], 2015 |  |
| Family factors: dysfunction, poor social support, negative attitudes | Aagaard *et al*[112], 1988; Drotar *et al*[133], 2007; Cely *et al*[83], 2011; Sajatovic *et al*[162], 2011a; Scott *et al*[140], 2012; Sharma *et al*[94], 2012; Col *et al*[141], 2014  | Sajatovic *et al*[72], 2009a; Sajatovic *et al*[86], 2011b |  |

BD: Bipolar disorder.

**Table 6 Studies of clinical correlates of medication non-adherence in bipolar disorder**

|  |  |  |  |
| --- | --- | --- | --- |
| **Clinical correlates**  | **Studies with positive associations** | **Studies without positive associations** | **Others** |
| Early age of onset | Aagaard *et al*[112], 1988; Maarbjerg *et al*[113], 1988; Drotar *et al*[133], 2007 Perlis *et al*[82], 2010; Barraco *et al*[88], 2012 | Colom *et al*[51], 2000; Scott and Pope[127], 2002a; Sajatovic *et al*[59], 2006a; Gonzalez-Pinto *et al*[132], 2006; Gonzalez-Pinto *et al*[78], 2010; Murru *et al*[90], 2012; Levin *et al*[106], 2015; Azadforouz *et al*[108], 2016 | Later onset - Col *et al*[141], 2014 Hajda *et al*[104], 2015 |
| Short durations of illness | Aagaard *et al*[112], 1988; Maarbjerg *et al*[113], 1988; Gonzalez-Pinto *et al*[78], 2010; Belzeaux *et al*[95], 2013; Azadforouz *et al*[108], 2016 | Danion *et al*[111], 1987; Aagaard and Vestergaard[118],1990; Schuman *et al*[123], 1999; Colom *et al*[51], 2000; Licht *et al*[125], 2001; Scott and Pope[127], 2002a; Jose *et al*[161],2003; Gonzalez-Pinto *et al*[132], 2006; Taj *et al*[69], 2008; Sajatovic *et al*[72], 2009a; Hou *et al*[79], 2010; Savas *et al*[85], 2011; Murru *et al*[90], 2012; Sharma *et al*[94], 2012; Montes *et al*[150], 2013; Col *et al*[141], 2014 | Longer durations - Coletti *et al*[57], 2005; Belzeaux *et al*[95], 2013 |
| Greater number of hospitalizations | Aagaard *et al*[112], 1988; Maarbjerg *et al*[113], 1988; Aagaard and Vestergaard[118],1990; Colom *et al*[51], 2000; Svarstad *et al*[52], 2001; Scott[126], 2002;; Scott and Pope[128], 2002b; Gonzalez-Pinto *et al*[132], 2006; Baldessarini *et al*[138], 2008b; Gianfrancesco *et al*[168], 2008; Hassan and Lage[145], 2009; Lage and Hasan[146], 2009; Martinez-Aran *et al*[74],2009; Vega *et al*[139], 2009; Bates *et al*[76], 2010; Gonzalez-Pinto *et al*[78], 2010; Hong *et al*[84], 2011; Lang *et al*[147], 2011; Savas *et al*[85], 2011; Scott *et al*[140], 2012; Kutzelnigg *et al*[151], 2014 | Johnson and McFarland[169], 1996; Keck *et al*[47], 1996a; Schuman *et al*[123], 1999; Jose *et al*[161],2003; Sajatovic *et al*[59], 2006a; [Sajatovic *et al*[143], 2006b;](http://www.ncbi.nlm.nih.gov/pubmed/?term=Greil%20W%5BAuthor%5D&cauthor=true&cauthor_uid=15291686) Sajatovic *et al*[144], 2007b; Sajatovic *et al*[40], 2008; Clatworthy *et al*[71], 2009; Sharifi *et al*[73], 2009; Bauer *et al*[44], 2010; Gonzalez-Pinto *et al*[78], 2010; Hou *et al*[79], 2010; Murru *et al*[90], 2012; Sharma *et al*[94], 2012; Montes *et al*[150], 2013; Hajda *et al*[104], 2015; Azadforouz *et al*[108], 2016 | Fewer hospitalizations - Sajatovic *et al*[137], 2007a; Col *et al*[141], 2014 |
| Higher total number of episodes | Danion *et al*[111], 1987; Gonzalez-Pinto *et al*[132], 2006; Vega *et al*[139], 2009; Gutiérrez-Rojas *et al*[81], 2010; Murru *et al*[100], 2013 | Lenzi *et al*[116], 1989; Keck *et al*[47], 1996a; Jose *et al*[161],2003; Martinez-Aran *et al*[74], 2009; Murru *et al*[90], 2012; Belzeaux *et al*[95], 2013; Col *et al*[141], 2014 | Fewer episodes - Colom *et al*[51], 2000 |
| Higher number of manic episodes | Gonzalez-Pinto *et al*[132], 2006; Vega *et al*[139], 2009; Murru *et* *al*[100], 2013 | Johnson *et al*[61], 2007; Zeber *et al*[68], 2008; Martinez-Aran *et al*[74], 2009; Bates *et al*[76], 2010; Gutiérrez-Rojas *et al*[81], 2010; Murru *et al*[90], 2012; Col *et al*[141], 2014 | Fewer hypomanic episodes - Colom *et al*[51], 2000 |
| Higher number of depressive episodes | Danion *et al*[111], 1987; Gutiérrez-Rojas *et al*[81], 2010; Col *et al*[141], 2014 | Gonzalez-Pinto *et al*[132], 2006; Johnson *et al*[61], 2007; Martinez-Aran *et al*[74], 2009; Vega *et al*[139], 2009; Bates *et al*[76], 2010; Murru *et al*[90], 2012 | Fewer depressive episodes - Colom *et al*[51], 2000 |
| Higher number of mixed episodes/rapid cycling | Calabrese *et al*[56], 2005; Perlis *et al*[82], 2010 | Maarbjerg *et al*[113], 1988; Colom *et al*[51], 2000; Sajatovic *et al*[59], 2006a; Gonzalez-Pinto *et al*[132], 2006; Sajatovic *et al*[40], 2008; Martinez-Aran *et al*[74], 2009; Murru *et al*[90], 2012; Murru *et al*[100], 2013 |  |
| BD *vs* UP disorders  | Arvilommi *et al*[101], 2014; Mert *et al*[107], 2015 | Connelly *et al*[109], 1982; Maarbjerg *et al*[113], 1988; Lenzi *et al*[116], 1989; Aagaard and Vestergaard[118], 1990; Schuman *et al*[123], 1999; McCleod and Sharp[37], 2001; Scott and Pope[127], 2002a; Taj *et al*[69], 2008; Ghaffari-Nejad *et al*[103], 2015 |  |
| BP I *vs* BP II | Martinez-Aran *et al*[74], 2009; Mazza *et al*[75], 2009 | Jamison *et al*[9], 1979; Colom *et al*[51], 2000; Sajatovic *et al*[59], 2006a; Sajatovic *et al*[40], 2008; Baldessarini *et al*[66], 2008a; Baldessarini *et al*[138], 2008b; Bauer *et al*[44], 2010; Perlis *et al*[82], 2010; Montes *et al*[150], 2013; Sylvia *et al*[42], 2014 | Higher in BP II - Belzeaux *et al*[100], 2013 |
| Polarity of episodes | Gutiérrez-Rojas *et al*[81], 2010; Montes *et al*[150], 2013 | Danion *et al*[111], 1987; Maarbjerg *et al*[113], 1988; Sajatovic *et al*[59], 2006a; Col *et al*[141], 2014 |  |
| Overall severity of illness | Baldessarini *et al*[66], 2008a; Sajatovic *et al*[72], 2009a; Sajatovic *et al*[40], 2008; Bates *et al*[76], 2010; Gonzalez-Pinto *et al*[78], 2010; Cely *et al*[83], 2011; Barraco *et al*[88], 2012; Sharma *et al*[94], 2012; Kutzelnigg *et al*[151], 2014; Hajda *et al*[104], 2015 | Danion *et al*[111], 1987; Nilsson and Axelsson[117], 1989; Sajatovic *et al*[63], 2007 c; Sajatovic *et al*[72], 2009a; Mazza *et al*[75], 2009; Hong *et al*[84], 2011; Sajatovic *et al*[86], 2011b; Montes *et al*[150], 2013; Sylvia *et al*[42], 2014; Azadforouz *et al*[108], 2016; Sajatovic *et al*[152], 2016 |  |
| Manic symptoms | Van Putten[20], 1975; Connelly *et al*[109], 1982; Keck *et al*[47], 1996a; Keck *et al*[142], 1996b; Lenzi *et al*[116], 1989; Miklowitz *et al*[171], 2000; Miklowitz *et al*[172], 2003; Bowden *et al*[130], 2005; Gonzalez-Pinto *et al*[132], 2006; Gaudiano and Miller[173], 2006; Baldessarini *et al*[66], 2008a; Copeland *et al*[67], 2008; Bauer *et al*[44], 2010; Gonzalez-Pinto *et al*[78], 2010; Perlis *et al*[82], 2010; Hong *et al*[84], 2011; Barraco *et al*[88], 2012; Montes *et al*[150], 2013; Sylvia *et al*[42], 2014; Levin *et al*[106], 2015 | Colom *et al*[51], 2000; Rosa *et al*[136], 2007; Sajatovic *et al*[59], 2006a; Sajatovic *et al*[63], 2007 c; Sajatovic *et al*[40], 2008; Clatworthy *et al*[71], 2009; Mazza *et al*[75],2009; Martinez-Aran *et al*[74], 2009; Sajatovic *et al*[86], 2011b; Murru *et al*[90], 2012; Belzeaux *et al*[95], 2013; Hibdye *et al*[98], 2013; Jonsdottir *et al*[99], 2013; Ghaffari-Nejad *et al*[103], 2015; Azadforouz *et al*[108], 2016; Sajatovic *et al*[152], 2016 |  |
| Depressive symptoms | Bowden *et al*[130], 2005; Gaudiano and Miller[173], 2006; Johnson *et al*[61], 2007; Martinez-Aran *et al*[74], 2009; Bates *et al*[76], 2010; Bauer *et al*[44], 2010; Perlis *et al*[82], 2010; Hong *et al*[84], 2011; Barraco *et al*[88], 2012; Montes *et al*[150], 2013; Arvilommi *et al*[101], 2014; Bauer *et al*[45], 2013a; Bauer *et al*[153], 2013b; Belzeaux *et al*[100], 2013; Gibson *et al*[97], 2013; Levin *et al*[106], 2015; Azadforouz *et al*[108], 2016; Sajatovic *et al*[152], 2016 | Colom *et al*[51], 2000; Miklowitz *et al*[171], 2000; Miklowitz *et al*[172], 2003; [Sajatovic *et al*[143], 2006b;](http://www.ncbi.nlm.nih.gov/pubmed/?term=Greil%20W%5BAuthor%5D&cauthor=true&cauthor_uid=15291686) Sajatovic *et al*[63], 2007 c; Rosa *et al*[136], 2007; Sajatovic *et al*[40], 2008; Sajatovic *et al*[72], 2009a; Clatworthy *et al*[71], 2009; Gonzalez-Pinto *et al*[78], 2010; Sajatovic *et al*[86], 2011b; Murru *et al*[90], 2012; Hibdye *et al*[98], 2013; Sylvia *et al*[42], 2014; Ghaffari-Nejad *et al*[103], 2015 | Better adherence with depression - Lenzi *et al*[116], 1989 |
| Mixed symptoms | Bowden *et al*[130], 2005; Gonzalez-Pinto *et al*[78], 2010; Perlis *et al*[82], 2010 | Licht *et al*[125], 2001; Azorin *et al*[70], 2009; Hibdye *et al*[98], 2013; Ghaffari-Nejad *et al*[103], 2015 |  |
| Psychotic symptoms | Miklowitz *et al*[174], 1992; Maj *et al*[122], 1998; Yen *et al*[157], 2005; Martinez-Aran *et al*[74], 2009; Gonzalez-Pinto *et al*[78], 2010; Murru *et al*[90], 2012; Murru *et al*[100], 2013; Levin *et al*[106], 2015; Sajatovic *et al*[152], 2016 | Danion *et al*[111], 1987; Aagaard and Vestergaard[118], 1990; Colom *et al*[51], 2000; Sajatovic *et al*[59], 2006a; Sajatovic *et al*[40], 2008; Sajatovic *et al*[72], 2009a; Perlis *et al*[82], 2010; Belzeaux *et al*[95], 2013; Azadforouz *et al*[108], 2016 |  |
| Cognitive impairment | Danion *et al*[111], 1987; Jose *et al*[161],2003; Baldessarini *et al*[66], 2008a; Depp *et al*[175], 2008; Martinez-Aran *et al*[74], 2009; Eker and Harkin[89], 2012 | Maarbjerg *et al*[113], 1988; Jonsdottir *et al*[99], 2013 |  |
| Familial psychiatric disorder | Drotar *et al*[133], 2007 | Colom *et al*[51], 2000; Gonzalez-Pinto *et al*[132], 2006; Martinez-Aran *et al*[74], 2009; Savas *et al*[85], 2011; Murru *et al*[90], 2012; Col *et al*[141], 2014; Hajda *et al*[104], 2015 |  |
| Poor insight | Schuman *et al*[123], 1999; Greenhouse *et al*[54], 2000; Jose *et al*[161],2003; Fleck *et al*[58], 2005; Yen *et al*[157], 2005; Rosa *et al*[160], 2006; Rosa *et al*[136], 2007; Copeland *et al*[67], 2008; Sajatovic *et al*[72], 2009a; Gonzalez-Pinto *et al*[78], 2010; Cely *et al*[83], 2011; Sajatovic *et al*[86], 2011b; Savas *et al*[85], 2011; Vieta *et al*[93], 2012; Kutzelnigg *et al*[151], 2014; Mert *et al*[107], 2015; Novick *et al*[176], 2015  | Wong *et al*[124], 1999; Jonsdottir *et al*[99], 2013 |  |
| Comorbid SUD | Aagaard *et al*[112], 1988; Maarbjerg *et al*[113], 1988; Weiss *et al*[50], 1998; Aagaard and Vestergaard[118],1990; Keck *et al*[121], 1997; Keck *et al*[48], 1998; Stratkowski *et al*[49], 1998; Licht *et al*[125], 2001; Fleck *et al*[58], 2005; Gonzalez-Pinto *et al*[132], 2006; Sajatovic *et al*[59], 2006a; [Sajatovic *et al*[143], 2006b;](http://www.ncbi.nlm.nih.gov/pubmed/?term=Greil%20W%5BAuthor%5D&cauthor=true&cauthor_uid=15291686) Sajatovic *et al*[137], 2007a; Sajatovic *et al*[144], 2007b; DelBello *et al*[60], 2007; Manwani *et al*[135], 2007; Baldessarini *et al*[138], 2008b; Copeland *et al*[67], 2008; Darling *et al*[177], 2008; Zeber *et al*[68], 2008; Sajatovic *et al*[72], 2009a; van Rossum *et al*[178],2009; Vega *et al*[139], 2009; Bates *et al*[76], 2010; Gonzalez-Pinto *et al*[78], 2010; Perlis *et al*[82], 2010; Cely *et al*[83], 2011; Hong *et al*[84], 2011; Lang *et al*[147], 2011; Sajatovic *et al*[162],2011a; Teter *et al*[179]*,* 2011; Barraco *et al*[88], 2012; Vieta *et al*[93], 2012; Hibdye *et al*[98], 2013; Jonsdottir *et al*[99], 2013; Montes *et al*[150], 2013; Arvilommi *et al*[101], 2014 | Nilsson and Axelsson[117],1989; Schuman *et al*[123], 1999; Colom *et al*[51], 2000; Sajatovic *et al*[63], 2007c; Sajatovic *et al*[40], 2008; Mazza *et al*[75], 2009; Sharifi *et al*[73],2009; Rascati *et al*[148],2011; Sajatovic *et al*[86], 2011b; Murru *et al*[90], 2012; Sharma *et al*[94], 2012 Murru *et al*[100], 2013; Col *et al*[141], 2014; Kutzelnigg *et al*[151], 2014; Sylvia *et al*[42], 2014; Mert *et al*[107], 2015; Ghaffari-Nejad *et al*[103], 2015 |  |
| Comorbid personality disorders | Danion *et al*[111], 1987; Aagaard *et al*[112], 1988; Maarbjerg *et al*[113], 1988; Colom *et al*[51], 2000; Murru *et al*[100], 2013; Arvilommi *et al*[101], 2014 | Aagaard and Vestergaard[118],1990; Schuman *et al*[123],1999; Kliendienst and Griel[156], 2004; Mazza *et al*[75], 2009; Murru *et al*[90], 2012; Kutzelnigg *et al*[151], 2014 |  |
| Comorbid anxiety disorders or ADHD | DelBello *et al*[60], 2007; Baldessarini *et al*[66], 2008a; Taj *et al*[69], 2008; Perlis *et al*[82], 2010; Arvilommi *et al*[101], 2014 | Sajatovic *et al*[59], 2006a; Sajatovic *et al*[144], 2007b; Drotar *et al*[133], 2007; Sajatovic *et al*[40], 2008; Cely *et al*[83], 2011; Rascati *et al*[148],2011; Murru *et al*[90], 2012; Belzeaux *et al*[95], 2013; Kutzelnigg *et al*[151], 2014; Sylvia *et al*[42], 2014 | Better adherence with comorbid anxiety disorder - Baldessarini *et al*[138], 2008b |

ADHD: Attention deficit hyperactivity disorder; BD: Bipolar disorder; SUD: Substance use disorders; UP: Unipolar disorder.

**Table 7 Studies of treatment correlates of medication non-adherence in bipolar disorder**

|  |  |  |  |
| --- | --- | --- | --- |
| **Treatment correlates** | **Studies with positive associations** | **Studies without positive associations** | **Others** |
| Differences between mood stabilizers | Weiss *et al*[50], 1998; Revicki *et al*[155], 2005; Baldessarini *et al*[138], 2008b; Sajatovic *et al*[137], 2007a | Baldessarini *et al*[66], 2008a; Darling *et al*[177], 2008; Bauer *et al*[45], 2013a; Col *et al*[141], 2014 |  |
| Differences between antipsychotics | Gianfrancesco *et al*[184], 2005; Gianfrancesco *et al*[185], 2006; Hassan *et al*[186], 2007; Sajatovic *et al*[144], 2007b; Rascati *et al*[148],2011; Ibrahim *et al*[105], 2015 | Patel *et al*[131], 2005; [Sajatovic *et al*[143], 2006b;](http://www.ncbi.nlm.nih.gov/pubmed/?term=Greil%20W%5BAuthor%5D&cauthor=true&cauthor_uid=15291686)  Baldessarini *et al*[66], 2008a |  |
| Differences between mood stabilizers and antipsychotics or antidepressants | Gonzalez-Pinto *et al*[78], 2010; Lang *et al*[147], 2011; Murru *et al*[100], 2013; Arvilommi *et al*[101], 2014; Ibrahim *et al*[105], 2015 | Danion *et al*[111], 1987; Keck *et al*[48], 1998; Colom *et al*[51], 2000; Patel *et al*[131], 2005; [Sajatovic *et al*[143], 2006b;](http://www.ncbi.nlm.nih.gov/pubmed/?term=Greil%20W%5BAuthor%5D&cauthor=true&cauthor_uid=15291686)  Baldessarini *et al*[66], 2008a; Azorin *et al*[70], 2009; Clatworthy *et al*[71], 2009; Gianfrancesco *et al*[187], 2009; Martinez-Aran *et al*[74], 2009; Mazza *et al*[75], 2009; Bates *et al*[76], 2010; Cely *et al*[83], 2011; Savas *et al*[85], 2011; Murru *et al*[90], 2012; Bauer *et al*[153], 2013b; Hibdye *et al*[98], 2013; Arvilommi *et al*[101], 2014; Hajda *et al*[104], 2015 |  |
| Shorter duration of treatment | Johnson and McFarland[169], 1996; Colom *et al*[51], 2000; Lang *et al*[147], 2011; Azadforouz *et al*[108], 2016 | Gonzalez-Pinto *et al*[132], 2006; Drotar *et al*[133], 2007; Darling *et al*[177], 2008; Sharma *et al*[94], 2012; Hibdye *et al*[98], 2013; Col *et al*[141], 2014 | Longer durations - Jamison *et al*[9], 1979; Scott and Pope[127], 2002a Kessing *et al*[134], 2007Sharifi *et al*[73], 2009; Short and long durations - Kutzelnigg *et al*[151], 2014 |
| Greater number of medications | Keck *et al*[47], 1996a; Revicki *et a*l[155], 2005; Baldessarini *et al*[138], 2008b; Gianfrancesco *et al*[187], 2009; Bates *et al*[76], 2010; Hou *et al*[79], 2010; Perlis *et al*[82], 2010; Cruz *et al*[35], 2011; Rascati *et al*[148],2011; Bauer *et al*[45], 2013a; Bauer *et al*[153], 2013b; Ibrahim *et al*[105], 2015 | Colom *et al*[51], 2000; Licht *et al*[125], 2001; Rosa *et al*[136], 2007; Baldessarini *et al*[66], 2008a; Darling *et al*[177], 2008; Depp *et al*[175], 2008; Taj *et al*[69], 2008; Martinez-Aran *et al*[74], 2009; Bauer *et al*[44], 2010; Sajatovic *et al*[86], 2011b; Savas *et al*[85],2011; Miasso *et al*[91], 2012; Sharma *et al*[94], 2012; Col *et al*[141], 2014; Ghaffari-Nejad *et al*[103], 2015 | Less intensive treatment - Johnson and McFarland[169], 1996; Keck *et al*[121], 1997; Sajatovic *et al*[59], 2006a; [Sajatovic *et al*[143], 2006b;](http://www.ncbi.nlm.nih.gov/pubmed/?term=Greil%20W%5BAuthor%5D&cauthor=true&cauthor_uid=15291686) Sajatovic *et al*[137], 2007a; Sajatovic *et al*[144], 2007b; Sajatovic *et al*[40], 2008 |
| Higher doses of medications | McCleod and Sharp[37], 2001; Gianfrancesco *et al*[185], 2006 | Baldessarini *et al*[66], 2008a; Col *et al*[141], 2014; Hajda *et al*[104], 2015 | Lower doses of medications - Mazza *et al*[75], 2009; Bauer *et al*[44], 2010 |
| Complex medication regimens | Baldessarini *et al*[138], 2008b; Sajatovic *et al*[72], 2009a; Hibdye *et al*[98], 2013; Ibrahim *et al*[105], 2015 | Keck *et al*[48], 1998; Baldessarini *et al*[66], 2008a; Miasso *et al*[91], 2012; Col *et al*[141], 2014 |  |
| Side effects | Bech *et al*[30], 1976; Vestergaard and Amdisen[188], 1983; Maarbjerg *et al*[113], 1988; Gitlin *et a*l[189], 1989; Nilsson and Axelsson[117], 1989; Aagaard and Vestergaard[118],1990; Maj *et al*[122], 1998; Weiss *et al*[50], 1998; Licht *et al*[125], 2001; Kliendienst and Griel[156], 2004; Lewis[190], 2005; Bowden *et al*[130], 2005; Calabrese *et al*[56], 2005; Fleck *et al*[58], 2005; Revicki *et a*l[155], 2005; Johnson *et al*[61], 2007; Baldessarini *et al*[66], 2008a; Baldessarini *et al*[138], 2008b; Bates *et al*[76], 2010; Mączka *et al*[191], 2010; Wang and Henning[192], 2010; Cely *et al*[83], 2011; Cruz *et al*[35], 2011; Miasso *et al*[193], 2011; Sajatovic *et al*[162], 2011a; Teter *et al*[1179]*,* 2011; Eker and Harkin[89], 2012; Sharma *et al*[94], 2012; Belzeaux *et al*[95], 2013; Gibson *et al*[97], 2013; Arvilommi *et al*[101], 2014; Sylvia *et al*[42], 2014; Ibrahim *et al*[105], 2015; Mert *et al*[107], 2015 Ghaffari-Nejad *et al*[103], 2015 | Van Putten[20], 1975; Jamison *et al*[9], 1979; Connelly *et al*[109], 1982; Danion *et al*[111], 1987; Lenzi *et al*[116], 1989; Johnson and McFarland[169], 1996; Schuman *et al*[123], 1999; Scott[196], 2000; Scott[126], 2002; Scott and Pope[127], 2002a; Morselli *et al*[194], 2003; Morselli *et al*[195], 2004; Pope and Scott[129], 2003; Roy *et al*[33], 2005; [Sajatovic *et al*[143], 2006b;](http://www.ncbi.nlm.nih.gov/pubmed/?term=Greil%20W%5BAuthor%5D&cauthor=true&cauthor_uid=15291686) Drotar *et al*[133],2007; Rosa *et al*[160], 2006; Rosa *et al*[136], 2007; Perlis *et al*[82], 2010; Savas *et al*[85], 2011; Barraco *et al*[88], 2012; Vieta *et al*[93], 2012; Hibdye *et al*[98], 2013; Jonsdottir *et al*[99], 2013; Kutzelnigg *et al*[151], 2014; Col *et al*[141], 2014 | Fear of side effects - Cochran *et al*[31], 1984; Schuman *et al*[123], 1999; Scott[196], 2000; Scott[126], 2002; Scott and Pope[127], 2002a; Scott and Tacchi[197], 2002; Morselli *et al*[194], 2003; Morselli *et al*[195], 2004; Fleck *et al*[58], 2005; Rosa *et al*[160], 2006; Rosa *et al*[136], 2007; Clatworthy *et al*[36], 2007; Clatworthy *et al*[71], 2009; Sajatovic *et al*[198], 2009c; Kriegshauser *et al*[199], 2010; Cruz *et al*[35], 2011; Sajatovic *et a*l[162], 2011a |
| Efficacy | Bech *et al*[30], 1976; Jamison *et al*[9], 1979; Miklowitz *et al*[171], 2000; Miklowitz *et al*[172], 2003; Lewis[190], 2005; Fleck *et al*[58], 2005; Patel *et al*[131], 2005; Gaudiano and Miller[173], 2006; Drotar *et al*[133], 2007; Johnson *et al*[61], 2007; Sajatovic *et al*[198], 2009c; Cely *et al*[83], 2011 |  |  |

BD: Bipolar disorder. References in Tables 2-4 and text (No. 155-199).